





PA Criteria

Prior Authorization Group ABIRATERONE

Drug Names ABIRATERONE ACETATE, ABIRTEGA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Node-positive (N1), non-metastatic (M0) prostate cancer, very-high-risk prostate

cancer, non-metastatic high-risk prostate cancer, non-metastatic prostate cancer with prostate-specific antigen (PSA) persistence/recurrence after radical prostatectomy

Exclusion Criteria -

Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone

(GnRH) analog or after bilateral orchiectomy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ACITRETIN

Drug Names ACITRETIN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Prevention of non-melanoma skin cancers in high risk individuals, Lichen planus,

Keratosis follicularis (Darier Disease)

Exclusion Criteria -

Required Medical Information For psoriasis: The patient has experienced an inadequate treatment response,

intolerance, or has a contraindication to methotrexate or cyclosporine.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ACTIMMUNE
Drug Names ACTIMMUNE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Mycosis fungoides, Sezary syndrome

Exclusion Criteria - Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupAIMOVIGDrug NamesAIMOVIG

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For preventive treatment of migraine, continuation: The patient received at least 3

months of treatment with the requested drug and had a reduction in migraine days per

month from baseline.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Initial: 3 months, Continuation: Plan Year

Other Criteria -

Prior Authorization GroupAKEEGADrug NamesAKEEGA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone

(GnRH) analog or after bilateral orchiectomy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupALBENDAZOLEDrug NamesALBENDAZOLE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Ascariasis, trichuriasis, microsporidiosis

Exclusion Criteria -

Required Medical Information - Age Restrictions -

Prescriber Restrictions -

Coverage Duration Hydatid disease, Microsporidiosis: 6 months, All other indications: 1 month

Other Criteria -

Prior Authorization GroupALDURAZYMEDrug NamesALDURAZYME

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For mucopolysaccharidosis I (MPS I): Diagnosis was confirmed by an enzyme assay

demonstrating a deficiency of alpha-L-iduronidase enzyme activity and/or by genetic testing. Patients with Scheie form (i.e., attenuated MPS I) must have moderate to

severe symptoms.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ALECENSA
Drug Names ALECENSA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), brain metastases from ALK-positive NSCLC, ALK-positive anaplastic large-cell lymphoma (ALCL), Erdheim-Chester Disease (ECD) with ALK-fusion, inflammatory

myofibroblastic tumors (IMT) with ALK translocation, ALK-positive large B-cell

lymphoma

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or

metastatic OR 2) the requested drug will be used as adjuvant treatment following tumor

resection.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ALOSETRON

Drug NamesALOSETRON HYDROCHLORIDEPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For severe diarrhea-predominant irritable bowel syndrome (IBS): 1) The requested drug

is being prescribed for a biological female or a person that self-identifies as a female, 2) chronic IBS symptoms lasting at least 6 months, 3) gastrointestinal tract abnormalities have been ruled out, AND 4) inadequate treatment response to one conventional

therapy (e.g., antispasmodics, antidepressants, antidiarrheals).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ALPHA1-PROTEINASE INHIBITOR

Drug Names ARALAST NP, PROLASTIN-C, ZEMAIRA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For alpha1-proteinase inhibitor deficiency: Patient must have 1) clinically evident

emphysema, AND 2) pretreatment serum alpha1-proteinase inhibitor level less than 11 micromol/L (80 milligrams per deciliter [mg/dL] by radial immunodiffusion or 50 mg/dL

by nephelometry).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ALUNBRIG
Drug Names ALUNBRIG

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer

(NSCLC), brain metastases from ALK-positive NSCLC, inflammatory myofibroblastic tumors (IMT) with ALK translocation, Erdheim-Chester disease (ECD) with ALK-fusion

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or

metastatic, AND 2) the disease is anaplastic lymphoma kinase (ALK)-positive.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupALVAIZDrug NamesALVAIZ

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For chronic or persistent immune thrombocytopenia (ITP) (new starts): 1) Patient (pt) has experienced an inadequate treatment response or is intolerant to a prior therapy such as corticosteroids or immunoglobulins, AND 2) Untransfused platelet (plt) count at any point prior to the initiation of the requested medication is less than 30,000/mcL OR 30,000-50,000/mcL with symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a medical or dental procedure where blood loss is anticipated. comorbidities such as peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle that predisposes pt to trauma). For ITP (continuation): plt count response to the requested drug: 1) Current plt count is less than or equal to 200,000/mcL, OR 2) Current plt count is greater than 200,000/mcL to less than or equal to 400,000/mcL and dosing will be adjusted to a plt count sufficient to avoid clinically important bleeding. For thrombocytopenia associated with chronic hepatitis C (new starts): the requested drug is used for initiation and maintenance of interferon-based therapy. For thrombocytopenia associated with chronic hepatitis C (continuation): pt is receiving interferon-based therapy. For severe aplastic anemia (AA) (new starts): Pt had an insufficient response to immunosuppressive therapy.

Age Restrictions
Prescriber Restrictions
Coverage Duration

HCV: 6mo, ITP/AA initial: 6mo, ITP reauth: Plan Year, AA reauth: APR-Plan Year, IPR-

16 wks

Other Criteria

For severe AA (continuation): 1) Current plt count is 50,000-200,000/mcL, OR 2) Current plt count is less than 50,000/mcL and pt has not received appropriately titrated therapy for at least 16 weeks, OR 3) Current plt count is less than 50,000/mcL and pt is transfusion-independent, OR 4) Current plt count is greater than 200,000/mcL to less than or equal to 400,000/mcL and dosing will be adjusted to achieve and maintain an appropriate target plt count. APR: adequate platelet response (greater than 50,000/mcL), IPR: inadequate platelet response (less than 50,000/mcL).

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group ALYFTREK
Drug Names ALYFTREK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For cystic fibrosis: the requested drug will not be used in combination with other CFTR

(cystic fibrosis transmembrane conductance regulator) potentiating agents (e.g.,

ivacaftor, deutivacaftor).

Age Restrictions 6 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group AMBRISENTAN
Drug Names AMBRISENTAN

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group

1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood

units.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group AMPHETAMINES

Drug NamesAMPHETAMINE/DEXTROAMPHETAPA Indication IndicatorAll Medically-accepted Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or

Attention Deficit Disorder (ADD) OR 2) The patient has a diagnosis of narcolepsy

confirmed by a sleep study.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ARCALYST Drug Names ARCALYST

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Prevention of gout flares in patients initiating or continuing urate-lowering therapy

Exclusion Criteria -

For prevention of gout flares in patients initiating or continuing urate-lowering therapy (e.g., allopurinol) (new starts): 1) two or more gout flares within the previous 12 months, AND 2) inadequate response, intolerance, or contraindication to maximum tolerated doses of a non-steroidal anti-inflammatory drug (NSAID) and colchicine, AND 3) concurrent use with urate-lowering therapy. For prevention of gout flares in patients initiating or continuing urate-lowering therapy (e.g., allopurinol) (continuation): 1) patient must have achieved or maintained a clinical benefit (i.e., a fewer number of gout attacks or fewer flare days) compared to baseline, AND 2) continued use of urate-lowering therapy concurrently with the requested drug. For recurrent pericarditis:

maximum tolerated doses of a NSAID and colchicine.

patient must have had an inadequate response, intolerance, or contraindication to

Age Restrictions -Prescriber Restrictions --

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupARIKAYCEDrug NamesARIKAYCE

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupARMODAFINILDrug NamesARMODAFINIL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For excessive sleepiness associated with narcolepsy: The diagnosis has been

confirmed by sleep lab evaluation. For excessive sleepiness associated with

obstructive sleep apnea (OSA): The diagnosis has been confirmed by

polysomnography.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupAUGTYRODrug NamesAUGTYRO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group AUSTEDO

Drug Names AUSTEDO, AUSTEDO XR, AUSTEDO XR PATIENT TITRAT

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Tourette's syndrome

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupAUVELITYDrug NamesAUVELITY

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For Major Depressive Disorder (MDD): The patient has experienced an inadequate

treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin

reuptake inhibitors (SSRIs), mirtazapine, bupropion.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group AVMAPKI-FAZYNJA

Drug NamesAVMAPKI FAKZYNJA CO-PACKPA Indication IndicatorAll FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group AYVAKIT
Drug Names AYVAKIT

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Myeloid and lymphoid neoplasms with eosinophilia, gastrointestinal stromal tumor (GIST) for residual, unresectable, tumor rupture, or recurrent/metastatic disease without platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.

Exclusion Criteria -

Required Medical Information For myeloid and lymphoid neoplasms with eosinophilia, the patient meets all of the

following criteria: 1) The disease is FIP1L1- PDGFRA rearrangement-positive, AND 2) The disease harbors a PDGFRA D842V mutation, AND 3) The disease is resistant to imatinib. For GIST, the patient meets either of the following criteria: 1) The disease harbors PDGFRA exon 18 mutation, including a PDGFRA D842V mutation, OR 2) The requested drug will be used after failure on at least two Food and Drug Administration (FDA)-approved therapies in residual, unresectable, tumor rupture, or recurrent/metastatic disease without PDGFRA exon 18 mutation. For systemic

mastocytosis: 1) The patient has a diagnosis of indolent systemic mastocytosis or advanced systemic mastocytosis (including aggressive systemic mastocytosis [ASM], systemic mastocytosis with associated hematological neoplasm [SM-AHN], and mast cell leukemia [MCL]) AND 2) The patient has a platelet count of greater than or equal to

50,000/microliter (mcL).

Age Restrictions -Prescriber Restrictions --

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization Group Drug Names

B VS. D

ABELCET, ACETYLCYSTEINE, ACYCLOVIR SODIUM, ALBUTEROL SULFATE, AMPHOTERICIN B, AMPHOTERICIN B LIPOSOME, APREPITANT, ASTAGRAF XL, AZACITIDINE, AZATHIOPRINE, BENDAMUSTINE HYDROCHLORID, BENDEKA, BUDESONIDE, CALCITONIN-SALMON, CALCITRIOL, CARBOPLATIN, CINACALCET HYDROCHLORIDE, CISPLATIN, CLINIMIX 4.25%/DEXTROSE 1, CLINIMIX 4.25%/DEXTROSE 5, CLINIMIX 5%/DEXTROSE 15%, CLINIMIX 5%/DEXTROSE 20%. CLINIMIX 6/5. CLINIMIX 8/10. CLINIMIX 8/14. CLINISOL SF 15%. CLINOLIPID. CROMOLYN SODIUM, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE MONOHYDR, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYTARABINE AQUEOUS, DEXTROSE 50%, DEXTROSE 70%, DIPHTHERIA/TETANUS TOXOID. DOCETAXEL, DOCIVYX, DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE. DRONABINOL, ENGERIX-B, ETOPOSIDE, EVEROLIMUS, FIASP PUMPCART, FLUOROURACIL, FRINDOVYX, FULVESTRANT, GAMASTAN, GANCICLOVIR, GEMCITABINE HCL, GEMCITABINE HYDROCHLORIDE, GENGRAF. GRANISETRON HYDROCHLORIDE, HEPARIN SODIUM, HEPLISAV-B, HUMULIN R U-500 (CONCENTR, IBANDRONATE SODIUM, IMOVAX RABIES (H.D.C.V.), INTRALIPID, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE/ALBUT, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, JYLAMVO, JYNNEOS, KADCYLA, LEUCOVORIN CALCIUM, LEVALBUTEROL, LEVALBUTEROL HCL, LEVALBUTEROL HYDROCHLORID, LEVOCARNITINE, LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE, LIDOCAINE/PRILOCAINE, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETAT, METHYLPREDNISOLONE SODIUM, MORPHINE SULFATE, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID DR. NULOJIX, NUTRILIPID. ONDANSETRON HCL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON ODT, OXALIPLATIN, PACLITAXEL, PACLITAXEL PROTEIN-BOUND, PAMIDRONATE DISODIUM, PARICALCITOL, PEMETREXED, PENTAMIDINE ISETHIONATE, PLENAMINE, PREDNISOLONE, PREDNISOLONE SODIUM PHOSP, PREDNISONE, PREDNISONE INTENSOL, PREMASOL, PROGRAF, PROSOL, RABAVERT, RECOMBIVAX HB, SIROLIMUS, TACROLIMUS, TENIVAC, TPN ELECTROLYTES, TRAVASOL, TROPHAMINE, VINCRISTINE SULFATE, VINORELBINE TARTRATE, VIVIMUSTA, XATMEP, ZOLEDRONIC ACID

PA Indication Indicator

All Medically-accepted Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information Age Restrictions

Prescriber Restrictions

Coverage Duration

N/A

Other Criteria

This drug may be covered under Medicare Part B or D depending upon the

circumstances. Information may need to be submitted describing the use and setting of

the drug to make the determination.

Prior Authorization Group BAFIERTAM BAFIERTAM Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria** Required Medical Information Age Restrictions **Prescriber Restrictions**

Coverage Duration Plan Year

Other Criteria

BALVERSA Prior Authorization Group BALVERSA Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information For urothelial carcinoma: 1) disease has susceptible fibroblast growth factor receptor 3

> (FGFR3) genetic alterations, AND 2) the requested drug will be used as subsequent therapy for any of the following: a) locally advanced, recurrent, or metastatic urothelial carcinoma, OR b) stage II-IV, recurrent, or persistent urothelial carcinoma of the

bladder.

Age Restrictions **Prescriber Restrictions**

Coverage Duration

Plan Year

Other Criteria

Prior Authorization Group BANZEL RUFINAMIDE Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria** Required Medical Information

Age Restrictions 1 year of age or older

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization GroupBENLYSTADrug NamesBENLYSTA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria For patients new to therapy: severe active central nervous system lupus.

Required Medical Information For systemic lupus erythematosus (SLE): 1) patient is currently receiving a stable

standard therapy regimen for SLE (for example, corticosteroid, antimalarial, or NSAIDs), OR 2) patient has experienced an intolerance or has a contraindication to standard therapy regimen for SLE. For lupus nephritis: 1) patient is currently receiving a stable standard therapy regimen for lupus nephritis (for example, corticosteroid, cyclophosphamide, mycophenolate mofetil, or azathioprine) OR 2) patient has

experienced an intolerance or has a contraindication to standard therapy regimen for

lupus nephritis.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBERINERTDrug NamesBERINERT

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of acute angioedema attacks due to hereditary angioedema (HAE): 1)

the patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing, OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiopoietin-

1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-

sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose

antihistamine therapy for at least one month.

Age Restrictions

Prescriber RestrictionsPrescribed by or in consultation with an immunologist, allergist, or rheumatologist **Coverage Duration**Plan Year

Other Criteria -

Prior Authorization GroupBESREMIDrug NamesBESREMI

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBETASERONDrug NamesBETASERON

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBEXAROTENEDrug NamesBEXAROTENE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Mycosis fungoides (MF)/Sezary syndrome (SS), CD30-positive primary cutaneous

anaplastic large cell lymphoma (ALCL), CD30-positive lymphomatoid papulosis (LyP)

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBOSENTANDrug NamesBOSENTAN

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group

1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) if the request is for an adult patient, the patient meets both of the following: a) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units, and b) the patient has experienced an inadequate treatment response, intolerance, or

the patient has a contraindication to ambrisentan (Letairis).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group BOSULIF

Drug Names BOSULIF

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label UsesPhiladelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL), myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the

chronic phase or blast phase.

Exclusion Criteria -

Required Medical Information For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and

patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I, G250E, V299L, and F317L, AND 3) Patient has experienced resistance or intolerance to imatinib, dasatinib, or nilotinib. For B-ALL including patients who have received hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I, G250E, V299L,

and F317L.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group BRAFTOVI
Drug Names BRAFTOVI

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Adjuvant systemic therapy for cutaneous melanoma, appendiceal adenocarcinoma,

recurrent NSCLC

Exclusion Criteria -

Required Medical Information For colorectal cancer (including appendiceal adenocarcinoma): 1) Tumor is positive for

BRAF V600E mutation, AND 2) The patient has either of the following: a) advanced or metastatic disease, b) unresectable metachronous metastases. For melanoma: 1) Tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with binimetinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer (NSCLC): 1) Tumor is positive for BRAF V600E mutation, AND 2) Disease is advanced, recurrent, or metastatic, AND 3) The requested drug will be used

in combination with binimetinib.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBRIVIACTDrug NamesBRIVIACT

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has

experienced an inadequate treatment response, intolerance, or has a contraindication

to a generic anticonvulsant AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom (if 4 years of age or older), Xcopri (if 18 years of age or older), Spritam (if 4

years of age or older).

Age Restrictions 1 month of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization GroupBRUKINSADrug NamesBRUKINSA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic

lymphoma (CLL/SLL): the patient has experienced an intolerable adverse event or has

a contraindication to Calquence (acalabrutinib).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupBUDESONIDE CAPDrug NamesBUDESONIDE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Induction and maintenance of clinical remission of microscopic colitis in adults,

autoimmune hepatitis

Exclusion Criteria -

Required Medical Information For the maintenance of clinical remission of microscopic colitis: patient has had a

recurrence of symptoms following discontinuation of induction therapy.

Age Restrictions Crohn's, treatment: 8 years of age or older

Prescriber Restrictions -

Coverage Duration Autoimmune hepatitis, Microscopic colitis, maintenance: 12 months, all other

indications: 3 months

Other Criteria -

Prior Authorization Group BUPRENORPHINE PATCH

Drug Names BUPRENORPHINE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has taken an immediate-release opioid for at least one week.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CABOMETYX
Drug Names CABOMETYX

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Non-small cell lung cancer, Ewing sarcoma, osteosarcoma, gastrointestinal stromal

tumor, endometrial carcinoma

Exclusion Criteria

Required Medical Information For renal cell carcinoma: The disease is advanced, relapsed, or stage IV (including

brain metastases). For non-small cell lung cancer: 1) the disease is rearranged during transfection (RET) positive AND 2) the disease is recurrent, advanced, or metastatic. For hepatocellular carcinoma: the requested drug will be used as subsequent therapy. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture, AND 2) the disease has progressed after at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib). For Ewing sarcoma and osteosarcoma: the requested drug will be used as subsequent therapy. For differentiated thyroid cancer (DTC) (follicular, papillary, oncocytic): 1) the disease is locally advanced or metastatic, AND 2) the disease has progressed after a vascular endothelial growth factor receptor (VEGFR)- targeted therapy, AND 3) the patient is refractory to radioactive iodine therapy (RAI) or ineligible for RAI. For endometrial carcinoma: 1) the disease is recurrent, AND 2) the requested drug will be used as subsequent therapy.

Age Restrictions --

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CALCIPOTRIENE

Drug Names CALCIPOTRIENE, CALCITRENE, ENSTILAR

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For psoriasis: The patient has experienced an inadequate treatment response,

intolerance, or has a contraindication to a topical steroid.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group CALQUENCE
Drug Names CALQUENCE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), marginal zone

lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, splenic

marginal zone lymphoma)

Exclusion Criteria -

Required Medical Information For marginal zone lymphoma (including extranodal marginal zone lymphoma of the

stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, and splenic marginal zone lymphoma): the requested drug is being used for

the treatment of relapsed, refractory, or progressive disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupCAPRELSADrug NamesCAPRELSA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Thyroid carcinomas (follicular, oncocytic, papillary).

Exclusion Criteria - Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CARBAGLU

Drug Names CARGLUMIC ACID

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information For N-acetylglutamate synthase (NAGS) deficiency: Diagnosis of NAGS deficiency was

confirmed by enzymatic, biochemical, or genetic testing.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupCAYSTONDrug NamesCAYSTON

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of respiratory symptoms in cystic fibrosis patients: 1) Pseudomonas

aeruginosa is present in the patient's airway cultures, OR 2) The patient has a history

of pseudomonas aeruginosa infection or colonization in the airways.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CEQUR

Drug Names CEQUR SIMPLICITY 2U, CEQUR SIMPLICITY INSERTER

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information Initial: 1) the patient has diabetes requiring insulin management AND 2) the patient is

currently self-testing glucose levels, the patient will be counseled on self-testing glucose levels, or the patient is using a continuous glucose monitor AND 3) the patient

meets either of the following: a) the patient has tried bolus injections and either did not meet glycemic goals or had difficulties administering multiple insulin injections daily, b)

the patient is unable to try bolus injections.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CERDELGA
Drug Names CERDELGA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For type 1 Gaucher disease (GD1): 1) Diagnosis was confirmed by an enzyme assay

demonstrating a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing, and 2) Patient's CYP2D6 metabolizer status has been established using an FDA-cleared test, and 3) Patient is a CYP2D6 extensive metabolizer, an intermediate

metabolizer, or a poor metabolizer.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group CEREZYME Drug Names CEREZYME

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Type 2 Gaucher disease, Type 3 Gaucher disease.

Exclusion Criteria

Required Medical Information For Gaucher disease: Diagnosis was confirmed by an enzyme assay demonstrating a

deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing.

Age Restrictions Prescriber Restrictions

Plan Year **Coverage Duration**

Other Criteria

Prior Authorization Group

CGM LCD L33822

Drug Names DEXCOM G6 RECEIVER, DEXCOM G6 SENSOR, DEXCOM G6 TRANSMITTER,

DEXCOM G7 RECEIVER, DEXCOM G7 SENSOR, FREESTYLE LIBRE 14 DAY/SE.

FREESTYLE LIBRE 2/READER/, FREESTYLE LIBRE 2/SENSOR/, FREESTYLE

LIBRE 3/READER/, FREESTYLE LIBRE 3/SENSOR/, FREESTYLE

LIBRE/READER/FL

PA Indication Indicator

All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information

To be eligible for coverage of a continuous glucose monitor (CGM) and related supplies, the beneficiary must meet all of the following initial coverage criteria (1)-(5): (1) Within six (6) months prior to ordering the CGM, the treating practitioner has an inperson or Medicare-approved telehealth visit with the beneficiary to evaluate their diabetes control and determined that criteria (2)-(5) below are met, AND (2) The beneficiary has diabetes mellitus, AND (3) The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the CGM prescribed, as evidenced by providing a prescription, AND (4) The CGM is prescribed in accordance with its FDA indications for use, AND (5) The beneficiary for whom a CGM is being prescribed, to improve glycemic control, meets at least one of the following criteria: (A) The beneficiary is insulin-treated OR (B) The beneficiary has a history of problematic hypoglycemia with documentation of at least one of the following: (I) Recurrent (more than one) level 2 hypoglycemic events (glucose less than 54mg/dL (3.0mmol/L)) that persist despite multiple (more than one) attempts to adjust medication(s) and/or modify the diabetes treatment plan OR (II) A history of one level 3 hypoglycemic event (glucose less than 54mg/dL (3.0mmol/L)) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia.

Age Restrictions **Prescriber Restrictions**

Plan Year **Coverage Duration**

Other Criteria

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization GroupCLOBAZAMDrug NamesCLOBAZAM

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Seizures associated with Dravet syndrome

Exclusion Criteria -

Required Medical Information

Age Restrictions Seizures associated with Lennox-Gastaut syndrome (LGS): 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CLOMIPRAMINE

Drug Names CLOMIPRAMINE HYDROCHLORID

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Depression, panic disorder

Exclusion Criteria -

Required Medical Information For obsessive-compulsive disorder (OCD) and panic disorder: The patient has

experienced an inadequate treatment response, intolerance, or the patient has a contraindication to any of the following: a serotonin and norepinephrine reuptake inhibitor (SNRI), a selective serotonin reuptake inhibitor (SSRI). For depression: The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to two of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine,

bupropion.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group CLORAZEPATE

Drug NamesCLORAZEPATE DIPOTASSIUMPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For all indications: The prescriber must acknowledge the benefit of therapy with this

prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs).

Age Restrictions Prescriber Restrictions -

Coverage Duration Short-term relief anxiety-1 month, Anxiety Disorders-4 months, All other Diagnoses-

Plan Year

Other Criteria This Prior Authorization only applies to patients 65 years of age or older.

Prior Authorization GroupCLOZAPINE ODTDrug NamesCLOZAPINE ODT

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group COBENFY

Drug Names COBENFY, COBENFY STARTER PACK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of schizophrenia: 1) The patient experienced an inadequate treatment

response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta,

Lybalvi, Rexulti, Secuado, Vraylar.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group COMETRIQ
Drug Names COMETRIQ

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Non-small cell lung cancer (NSCLC), thyroid carcinomas (follicular, oncocytic,

papillary).

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC): Disease is positive for rearranged during

transfection (RET) rearrangements.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group COPIKTRA
Drug Names COPIKTRA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Hepatosplenic T-Cell lymphoma, breast implant-associated anaplastic large cell

lymphoma (ALCL), peripheral T-Cell lymphoma

Exclusion Criteria -

Required Medical Information For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), breast

implant-associated anaplastic large cell lymphoma (ALCL), and peripheral T-Cell lymphoma: the patient has relapsed or refractory disease. For hepatosplenic T-Cell

lymphoma: the patient has refractory disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group

Drug Names

COSENTYX, COSENTYX SENSOREADY PEN, COSENTYX UNOREADY

PA Indication Indicator

Off-label Uses

All FDA-approved Indications

Exclusion Criteria

-

COSENTYX

Required Medical Information

For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp. neck, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Pyzchiva (ustekinumabttwe), Skyrizi (risankizumab-rzaa), Sotyktu (deucravacitinib), Stelara (ustekinumab), Tremfya (guselkumab), Yesintek (ustekinumab-kfce). For active ankylosing spondylitis (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumabaacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Rinvog (upadacitinib), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib extended-release). For active non-radiographic axial spondyloarthritis (new starts only): patient meets any of the following: 1) patient has experienced an inadequate treatment response to a nonsteroidal anti-inflammatory drug (NSAID) OR 2) patient has experienced an intolerance or has a contraindication to NSAIDs. For an adult with active psoriatic arthritis (PsA) (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumabaacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Pyzchiva (ustekinumab-ttwe), Rinvoq (upadacitinib)/Rinvoq LQ (upadacitinib), Skyrizi (risankizumab-rzaa), Stelara (ustekinumab), Tremfya (guselkumab), Xeljanz (tofacitinib)/Xelianz XR (tofacitinib extended-release), Yesintek (ustekinumab-kfce).

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

Plan Year

For moderate to severe hidradenitis suppurativa (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Humira (adalimumab), Idacio (adalimumab-aacf).

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupCOTELLICDrug NamesCOTELLIC

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Central nervous system (CNS) cancer (i.e., glioma, glioblastoma), adjuvant systemic

therapy for cutaneous melanoma.

Exclusion Criteria -

Required Medical Information For central nervous system (CNS) cancer (i.e., glioma, glioblastoma): 1) The tumor is

positive for BRAF V600E activating mutation, AND 2) The requested drug will be used in combination with vemurafenib. For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used in combination with vemurafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b)

adjuvant systemic therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupCYSTADROPSDrug NamesCYSTADROPS

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For cystinosis: 1) Diagnosis was confirmed by ANY of the following: a) the presence of

increased cystine concentration in leukocytes, OR b) genetic testing, OR c)

demonstration of corneal cystine crystals by slit lamp examination, AND 2) the patient

has corneal cystine crystal accumulation.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupCYSTAGONDrug NamesCYSTAGON

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For nephropathic cystinosis: Diagnosis was confirmed by ANY of the following: 1) the

presence of increased cystine concentration in leukocytes, OR 2) genetic testing, OR

3) demonstration of corneal cystine crystals by slit lamp examination.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group CYSTARAN
Drug Names CYSTARAN

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For cystinosis: 1) Diagnosis was confirmed by ANY of the following: a) the presence of

increased cystine concentration in leukocytes, OR b) genetic testing, OR c)

demonstration of corneal cystine crystals by slit lamp examination, AND 2) the patient

has corneal cystine crystal accumulation.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupDALFAMPRIDINEDrug NamesDALFAMPRIDINE ER

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For multiple sclerosis, patient must meet the following (for new starts): prior to initiating

therapy, patient demonstrates sustained walking impairment. For multiple sclerosis (continuation): patient must have experienced an improvement in walking speed OR

other objective measure of walking ability since starting the requested drug.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DANZITEN
Drug Names DANZITEN

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), pigmented

villonodular synovitis/tenosynovial giant cell tumor

Exclusion Criteria -

Required Medical Information For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and

patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor for CML, patient is negative for T315I, Y253H, E255K/V, and F359V/C/I mutations. For acute lymphoblastic leukemia (ALL), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If the patient has experienced resistance to an alternative tyrosine kinase inhibitor for ALL, patient is negative for T315I, Y253H,

E255K/V, F359V/C/I and G250E mutations.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DARAPRIM

Drug Names PYRIMETHAMINE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Toxoplasmosis prophylaxis, Pneumocystis jirovecii pneumonia prophylaxis,

cystoisosporiasis treatment and secondary prophylaxis

Exclusion Criteria -

Required Medical Information For primary toxoplasmosis prophylaxis and Pneumocystis jirovecii pneumonia (PCP)

prophylaxis: 1) The patient has experienced an intolerance or has a contraindication to trimethoprim-sulfamethoxazole (TMP-SMX) AND 2) The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 3 months. For

secondary toxoplasmosis prophylaxis: The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 6 months. For cystoisosporiasis treatment: The patient has experienced an intolerance or has a contraindication to TMP-SMX. For secondary cystoisosporiasis prophylaxis: 1) The patient has

experienced an intolerance or has a contraindication to TMP-SMX AND 2) The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 6

months.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Congen toxo tx: Plan Yr. Acqu toxo tx, prim toxo ppx, PCP ppx: 3mo. Sec toxo ppx,

cysto tx/ppx: 6mo

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group DAURISMO
Drug Names DAURISMO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Post-induction therapy/consolidation following response to previous therapy with the

same regimen for acute myeloid leukemia (AML), relapsed/refractory AML as a

component of repeating the initial successful induction regimen

Exclusion Criteria -

Required Medical Information For acute myeloid leukemia (AML): 1) the requested drug must be used in combination

with cytarabine, 2) the patient is 75 years of age or older OR has comorbidities that preclude intensive chemotherapy, AND 3) the requested drug will be used as treatment for induction therapy, post-induction/consolidation therapy, or relapsed or refractory

disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupDEFERASIROXDrug NamesDEFERASIROX

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For chronic iron overload due to blood transfusions: pretreatment serum ferritin level is

greater than 1000 mcg/L.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DEMSER
Drug Names METYROSINE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or has a

contraindication to an alpha-adrenergic antagonist.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DEXMETHYLPHENIDATE

Drug Names DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HYDROC

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Cancer-related fatigue

Exclusion Criteria -

Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or

Attention Deficit Disorder (ADD) OR 2) The requested drug is being prescribed for the treatment of cancer-related fatigue after other causes of fatigue have been ruled out.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DHE NASAL

Drug Names DIHYDROERGOTAMINE MESYLAT

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Coverage will be denied when used in conjunction with potent CYP3A4 inhibitors (e.g.,

ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin).

Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or has a

contraindication to at least one triptan 5-HT1 receptor agonist.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DIACOMIT
Drug Names DIACOMIT

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions 6 months of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group DIAZEPAM

Drug Names DIAZEPAM, DIAZEPAM INTENSOL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For all indications: The prescriber must acknowledge the benefit of therapy with this

prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine

reuptake inhibitors (SNRIs).

Age Restrictions -

Prescriber Restrictions

Coverage Duration Short-term relief anx-1 mo, skeletal muscle spasm-3 mo, Anx Disorders-4 mo, Other

Diagnoses-PlanYR

Other Criteria This Prior Authorization only applies to patients 65 years of age or older. Applies to

greater than cumulative 5 days of therapy per year.

Prior Authorization GroupDOPTELETDrug NamesDOPTELET

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For thrombocytopenia in patients with chronic liver disease: Untransfused platelet count

prior to a scheduled procedure is less than 50,000/mcL. For chronic immune thrombocytopenia (ITP) (new starts): 1) Patient has experienced an inadequate treatment response or is intolerant to a prior therapy such as corticosteroids or immunoglobulins, AND 2) Untransfused platelet count at any point prior to the initiation of the requested medication is less than 30,000/mcL OR 30,000 to 50,000/mcL with symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a medical or dental procedure where blood loss is anticipated, comorbidities such as peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle that predisposes patient to trauma). For ITP (continuation): platelet count response to the requested drug: 1) Current platelet count is less than or equal to 200,000/mcL, OR 2) Current platelet count is greater than 200,000/mcL and less than or equal to 400,000/mcL and dosing will be adjusted to a platelet count sufficient to avoid clinically important

Age Restrictions 18 years of age or older

Prescriber Restrictions -

Coverage Duration Chronic liver disease: 1 month, ITP initial: 6 months, ITP continuation: Plan Year

Other Criteria -

Prior Authorization Group DRIZALMA

Drug Names DRIZALMA SPRINKLE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Cancer pain, chemotherapy-induced neuropathic pain

bleeding.

Exclusion Criteria -

Required Medical Information 1) The patient has tried duloxetine capsules OR 2) The patient is unable to take

duloxetine capsules for any reason (e.g., difficulty swallowing capsules, requires

nasogastric administration).

Age Restrictions Generalized Anxiety Disorder: 7 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupDUPIXENTDrug NamesDUPIXENT

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For atopic dermatitis (AD), initial therapy: 1) Patient has moderate-to-severe disease, AND 2) Patient has had an inadequate treatment response to either a topical corticosteroid or a topical calcineurin inhibitor. OR topical corticosteroids and topical calcineurin inhibitors are not advisable for the patient. For AD, continuation of therapy: Patient achieved or maintained positive clinical response. For oral corticosteroid dependent asthma, initial therapy: Patient has inadequate asthma control despite current treatment with both of the following medications: 1) High-dose inhaled corticosteroid AND 2) Additional controller (i.e., long acting beta2-agonist (LABA), longacting muscarinic antagonist (LAMA), leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For moderate-to-severe asthma, initial therapy: Patient has a baseline blood eosinophil count of at least 150 cells per microliter and their asthma remains inadequately controlled despite current treatment with both of the following medications: 1) Mediumto-high-dose inhaled corticosteroid, AND 2) Additional controller (i.e., LABA, LAMA, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For asthma, continuation of therapy: Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For chronic rhinosinusitis with nasal polyposis (CRSwNP): 1) The requested drug is used as add-on maintenance treatment, AND 2) For 18 years of age or older, patient has experienced an inadequate treatment response to Xhance (fluticasone).

Age Restrictions

Atopic Dermatitis: 6 months of age or older, Asthma: 6 years of age or older, Chronic Rhinosinusitis with Nasal Polyposis: 12 years of age or older, Chronic Obstructive Pulmonary Disease, Bullous Pemphigoid, and Prurigo Nodularis: 18 years of age or older, Eosinophilic Esophagitis: 1 year of age or older, CSU: 12 years of age or older

Prescriber Restrictions
Coverage Duration

AD, initial: 4 months, PN, initial: 6 months, CSU, initial: 6 months, All others: Plan Year

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Other Criteria

For eosinophilic esophagitis (EoE), initial therapy: 1) Diagnosis has been confirmed by esophageal biopsy characterized by greater than or equal to 15 intraepithelial esophageal eosinophils per high power field, AND 2) Patient is exhibiting clinical manifestations of the disease (for example, dysphagia), AND 3) Patient weighs at least 15 kilograms, AND 4) Patient experienced an inadequate treatment response, intolerance, or patient has a contraindication to a topical corticosteroid. For EoE, continuation of therapy: Patient achieved or maintained a positive clinical response. For prurigo nodularis (PN), continuation of therapy: Patient achieved or maintained a positive clinical response. For chronic obstructive pulmonary disease (COPD), initial therapy: 1) Patient is either of the following: a) currently receiving standard inhaled triple therapy (i.e., inhaled glucocorticoid, LAMA, and LABA) or b) currently receiving a LAMA and LABA, and has a contraindication to inhaled glucocorticoid, AND 2) Patient has an absolute blood eosinophil count of at least 300 cells per microliter prior to initiating therapy. For COPD, continuation of therapy: Patient achieved or maintained a positive clinical response. For chronic spontaneous urticaria (CSU), initial therapy: 1) Patient has been evaluated for other causes of urticaria, including bradykinin-related angioedema and interleukin-1 (IL-1)-associated urticarial syndromes (e.g., autoinflammatory disorders, urticarial vasculitis), 2) Patient has experienced a spontaneous onset of wheals, angioedema, or both, for at least 6 weeks, AND 3) Patient remains symptomatic despite H1 antihistamine treatment. For CSU, continuation of therapy: Patient has experienced a benefit (e.g., improved symptoms) since initiation of therapy. For bullous pemphigoid (BP), initial therapy: 1) Diagnosis has been confirmed by Direct immunofluorescence study OR Immune serological test(s), AND 2) Patient exhibits clinical manifestations of the disease (e.g., bullous lesions, excoriations, eczematous and/or urticarial erythematous lesions), AND 3) Prior to initiation with the requested drug the patient has had an inadequate treatment response to either a high-potency topical corticosteroid or systemic corticosteroid OR high-potency topical corticosteroids and systemic corticosteroids are not advisable for the patient. For BP, continuation of therapy: Patient achieved or maintained a positive clinical response.

Prior Authorization Group ELIGARD
Drug Names ELIGARD

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent androgen receptor positive salivary gland tumors

Exclusion Criteria Required Medical Information Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group EMGALITY
Drug Names EMGALITY

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For preventive treatment of migraine, continuation: The patient received at least 3

months of treatment with the requested drug and had a reduction in migraine days per month from baseline. For episodic cluster headache, initial: The patient experienced an inadequate treatment response, intolerance, or contraindication to a triptan 5-HT1 receptor agonist. For episodic cluster headache, continuation: The patient received the requested drug for at least 3 weeks of treatment and had a reduction in weekly cluster

headache attack frequency from baseline.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Initial: 3 months, Continuation: Plan Year

Other Criteria -

Prior Authorization GroupEMSAMDrug NamesEMSAM

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For Major Depressive Disorder (MDD): 1) The patient has experienced an inadequate

treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion OR 2) The patient is unable to

swallow oral formulations.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ENDARI

Drug Names L-GLUTAMINE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Required Medical Information -

Age Restrictions 5 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupEPCLUSADrug NamesEPCLUSA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum

prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance

Other Criteria -

Prior Authorization GroupEPIDIOLEXDrug NamesEPIDIOLEX

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions 1 year of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group EPRONTIA

Drug NamesEPRONTIA, TOPIRAMATEPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has

experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following:

Aptiom (if 4 years of age or older), Xcopri (if 18 years of age or older), Spritam (if 4 years of age or older). For monotherapy treatment of primary generalized tonic-clonic seizures: 1) The patient has experienced an inadequate treatment response or intolerance to a generic topiramate immediate release product, OR 2) The patient has difficulty swallowing solid oral dosage forms (e.g., tablets, capsules). For adjunctive treatment of primary generalized tonic-clonic seizures: 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) If the patient is 6 years of age or older, the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Spritam. For the preventative treatment of migraines: 1) The patient has experienced an inadequate treatment response or intolerance to a generic topiramate immediate release product, OR 2) The patient has difficulty swallowing solid oral dosage forms

(e.g., tablets, capsules).

Age Restrictions Epilepsy: 2 years of age or older, Migraine: 12 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ERGOTAMINE

Drug Names ERGOTAMINE TARTRATE/CAFFE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Coverage will be denied when used in conjunction with potent CYP3A4 inhibitors (e.g.,

ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin).

Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or has a

contraindication to at least ONE triptan 5-HT1 agonist.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupERIVEDGEDrug NamesERIVEDGE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Adult medulloblastoma

Exclusion Criteria -

Required Medical Information For adult medulloblastoma: patient has received prior systemic therapy AND has

tumor(s) with mutations in the sonic hedgehog pathway.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ERLEADA
Drug Names ERLEADA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone

(GnRH) analog or after bilateral orchiectomy.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ERLOTINIB

Drug Names ERLOTINIB HYDROCHLORIDE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent non-small cell lung cancer (NSCLC), recurrent chordoma, relapsed or stage

IV renal cell carcinoma (RCC), brain metastases from non-small cell lung cancer

(NSCLC), recurrent pancreatic cancer

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC) (including brain metastases from NSCLC): 1)

the disease is recurrent, advanced, or metastatic, AND 2) the patient has sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease. For pancreatic

cancer: the disease is locally advanced, unresectable, recurrent, or metastatic.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group ESBRIET

Drug Names PIRFENIDONE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For idiopathic pulmonary fibrosis (new starts only): 1) a high-resolution computed

tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial pneumonia (UIP) pattern, OR 2) HRCT study of the chest reveals a result other than the UIP pattern (e.g., probable UIP, indeterminate for UIP) and the diagnosis is supported either by a lung biopsy or by a multidisciplinary discussion between at least a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if

a lung biopsy has not been conducted.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Drug Names

ENBREL, ENBREL MINI, ENBREL SURECLICK

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications Hidradenitis suppurativa, non-radiographic axial spondyloarthritis

Exclusion Criteria

ETANERCEPT

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and nonradiographic axial spondyloarthritis (new starts only); patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plague psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate. cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e. at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). For hidradenitis suppurativa (new starts only): patient has severe, refractory disease.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

41 Updated: 10/01/2025

Drug Names

EVEROLIMUS, TORPENZ

EVEROLIMUS

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Classic Hodgkin lymphoma, thymomas and thymic carcinomas, previously treated

Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft tissue sarcoma

(perivascular epithelioid cell tumors (PEComa) and lymphangioleiomyomatosis

subtypes), gastrointestinal stromal tumors, neuroendocrine tumors of the thymus, well differentiated grade 3 neuroendocrine tumors, thyroid carcinoma (papillary, oncocytic,

and follicular), endometrial carcinoma, uterine sarcoma, breast cancer (in combination with fulvestrant or tamoxifen), histiocytic neoplasms (Rosai-Dorfman Disease, Erdheim-

Chester Disease, Langerhans Cell Histiocytosis), meningiomas.

Exclusion Criteria

Required Medical Information

For breast cancer: 1) The disease is recurrent unresectable, advanced, or metastatic

hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)negative, AND 2) The requested drug is prescribed in combination with exemestane,

fulvestrant, or tamoxifen, AND 3) The requested drug is used for subsequent treatment.

For renal cell carcinoma: The disease is relapsed, advanced, or stage IV. For subependymal giant cell astrocytoma (SEGA): The requested drug is given as adjuvant

treatment. For gastrointestinal stromal tumor: 1) The disease is residual, recurrent, unresectable, or metastatic/tumor rupture, AND 2) The disease has progressed after use of at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib,

ripretinib). For Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease, and Langerhans Cell Histiocytosis (LCH): the patient must have a phosphatidylinositol-4,5-

bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

_

Prior Authorization Group

Drug Names

FABRAZYME FABRAZYME

PA Indication Indicator

All FDA-approved Indications

Off-label Uses

_

Exclusion Criteria

Required Medical Information

For Fabry disease, the patient meets ANY of the following: 1) diagnosis of Fabry

disease was confirmed by an enzyme assay demonstrating a deficiency of alphagalactosidase enzyme activity or by genetic testing, OR 2) the patient is a symptomatic

obligate carrier.

Age Restrictions

-

Prescriber Restrictions

Plan Year

Coverage Duration
Other Criteria

.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group FANAPT

Drug Names FANAPT, FANAPT TITRATION PACK A, FANAPT TITRATION PACK C

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For treatment of schizophrenia: 1) The patient experienced an inadequate treatment

response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar. For acute treatment of manic or mixed episodes associated with bipolar I disorder: 1) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Lybalvi, Vraylar.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group FASENRA

Drug NamesFASENRA, FASENRA PENPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For severe asthma, initial therapy: 1) Either a) Patient has baseline blood eosinophil count of at least 150 cells per microliter OR b) Patient is dependent on systemic corticosteroids. AND 2) Patient has a history of severe asthma despite current treatment with both of the following medications: a) medium-to-high-dose inhaled corticosteroid AND b) additional controller (i.e., long-acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For severe asthma, continuation of therapy: Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For eosinophilic granulomatosis with polyangiitis (EGPA), initial therapy: patient has a history or the presence of an eosinophil count of more than 1000 cells per microliter or a blood eosinophil level of greater than 10 percent. For EGPA, continuation of therapy: patient has a beneficial response to treatment with the requested drug, as demonstrated by any of the following: 1) a reduction in the frequency of relapses, 2) a reduction in the daily oral corticosteroid dose, OR 3) no active vasculitis. Asthma: 6 years of age or older, EGPA: 18 years of age or older

Age Restrictions

Prescriber Restrictions
Coverage Duration

Other Criteria

Plan Year

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group FENTANYL PATCH

Drug Names FENTANYL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The requested drug is being prescribed for pain associated with cancer, sickle cell

disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has

taken an immediate-release opioid for at least one week.

Age Restrictions
-

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group FETZIMA

Drug Names FETZIMA, FETZIMA TITRATION PACK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information For major depressive disorder (MDD): The patient has experienced an inadequate

treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin

reuptake inhibitors (SSRIs), mirtazapine, bupropion.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupFINTEPLADrug NamesFINTEPLA

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupFIRMAGONDrug NamesFIRMAGON

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupFLUCYTOSINEDrug NamesFLUCYTOSINE

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration 6 weeks

Other Criteria -

Prior Authorization GroupFOTIVDADrug NamesFOTIVDA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For renal cell carcinoma: 1) The disease is advanced, relapsed, refractory or Stage IV,

AND 2) The patient has received two or more prior systemic therapies.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupFRUZAQLADrug NamesFRUZAQLA

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupFULPHILADrug NamesFULPHILA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Stem cell transplantation-related indications

Exclusion Criteria -

Required Medical Information If receiving chemotherapy, the requested drug will be administered at least 24 hours

after chemotherapy. For prophylaxis of myelosuppressive chemotherapy-induced febrile neutropenia: the patient must meet both of the following: 1) Patient has a solid tumor or non-myeloid cancer, AND 2) Patient is currently receiving or will be receiving

treatment with myelosuppressive anti-cancer therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 6 months

Other Criteria -

Prior Authorization Group FYCOMPA

Drug NamesFYCOMPA, PERAMPANELPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has

experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following:

Aptiom, Xcopri, Spritam. For adjunctive treatment of primary generalized tonic-clonic

seizures: 1) The patient has experienced an inadequate treatment response,

intolerance, or has a contraindication to a generic anticonvulsant AND 2) The patient

has experienced an inadequate treatment response, intolerance, or has a

contraindication to Spritam.

Age Restrictions Partial-onset seizures (i.e., focal-onset seizures): 4 years of age or older. Primary

generalized tonic-clonic seizures: 12 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group GATTEX **Drug Names** GATTEX

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For short bowel syndrome (SBS) initial therapy: 1) for an adult patient, the patient has

been dependent on parenteral support for at least 12 months OR 2) for a pediatric patient, the patient is dependent on parenteral support. For SBS continuation:

requirement for parenteral support has decreased from baseline while on therapy with

the requested drug.

Age Restrictions -

Prescriber Restrictions Prescribed by or in consultation with a gastroenterologist, gastrointestinal surgeon, or

nutritional support specialist.

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupGAVRETODrug NamesGAVRETO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent rearranged during transfection (RET) rearrangement-positive non-small cell

lung cancer, RET mutation-positive medullary carcinoma

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer, patient must meet all of the following: 1) The disease is

recurrent, advanced, or metastatic, AND 2) The tumor is rearranged during transfection

(RET) fusion-positive or RET rearrangement-positive.

Age Restrictions Non-small cell lung cancer: 18 years of age or older, Thyroid cancer: 12 years of age or

older

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group GILENYA

Drug Names FINGOLIMOD HYDROCHLORIDE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupGILOTRIFDrug NamesGILOTRIF

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC), patient meets either of the following: 1) has

sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease AND a) has experienced an intolerable adverse event or contraindication to erlotinib, gefitinib or osimertinib, OR 2) has metastatic squamous NSCLC that progressed after platinum-

based chemotherapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group GLATIRAMER

Drug Names COPAXONE, GLATIRAMER ACETATE, GLATOPA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupGOMEKLIDrug NamesGOMEKLI

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Required Medical Information -

Age Restrictions 2 years of age or older

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Drug Names

GENOTROPIN, GENOTROPIN MINIQUICK

PA Indication Indicator

All Medically-accepted Indications

GROWTH HORMONE

Off-label Uses

_

Exclusion Criteria

Pediatric patients with closed epiphyses

Required Medical Information

Pediatric growth hormone deficiency (GHD): Patient (pt) is a neonate or was diagnosed with GHD as a neonate OR meets any of the following: 1) younger than 2.5 years old (yo) with pre-treatment (pre-tx) height (ht) more than 2 standard deviations (SD) below mean and slow growth velocity OR 2) 2.5 yo or older AND one of the following: a) pre-tx 1-year ht velocity more than 2 SD below mean OR b) pre-tx ht more than 2 SD below mean and 1-year ht velocity more than 1 SD below mean, AND patient meets any of the following: 1) failed 2 pre-tx growth hormone (GH) stimulation tests (peak below 10 ng/mL), OR 2) pituitary/central nervous system (CNS) disorder (e.g., genetic defects, acquired structural abnormalities, congenital structural abnormalities) and pre-tx insulinlike growth factor-1 (IGF-1) more than 2 SD below mean. Turner syndrome (TS): 1) Confirmed by karyotyping AND 2) pre-tx ht is less than the 5th percentile for age. Small for gestational age (SGA): 1) Birth weight (wt) less than 2500g at gestational age (GA) greater than 37 weeks, OR birth wt or length below 3rd percentile for GA or at least 2 SD below mean for GA, AND 2) did not manifest catch-up growth by age 2.

Age Restrictions
Prescriber Restrictions

SGA: 2 years of age or older

Coverage Duration
Other Criteria

Prescribed by or in consultation with an endocrinologist, nephrologist, infectious disease specialist, gastroenterologist/nutritional support specialist, or geneticist. Plan Year

Adult GHD: Pt meets any of the following: 1) failed 2 pre-tx GH stimulation tests, OR 2) pre-tx IGF-1 more than 2 SD below mean AND failed 1 pre-tx GH stimulation test, OR 3) organic hypothalamic-pituitary disease (e.g., suprasellar mass with previous surgery and cranial irradiation) with 3 or more pituitary hormone deficiencies AND pre-tx IGF-1 more than 2 SD below mean, OR 4) genetic or structural hypothalamic-pituitary defects, OR 5) childhood-onset GHD with congenital (genetic or structural) abnormality of the hypothalamus/pituitary/CNS. For pediatric GHD, TS, SGA, and adult GHD, continuation of therapy: Patient is experiencing improvement.

Prior Authorization GroupHAEGARDADrug NamesHAEGARDA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the prophylaxis of angioedema attacks due to hereditary angioedema (HAE): 1) the

patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing, OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiopoietin-

1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-

sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose

antihistamine therapy for at least one month.

Age Restrictions 6 years of age or older

Prescriber RestrictionsPrescribed by or in consultation with an immunologist, allergist, or rheumatologist **Coverage Duration**Plan Year

Other Criteria -

Prior Authorization Group HARVONI
Drug Names HARVONI

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum

prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment

guidelines.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Criteria applied consistent w/ current AASLD-IDSA guidance. Reminder for 8wk option

if appropriate.

Other Criteria -

Drug Names

HERCEPTIN HERCEPTIN

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer.

Exclusion Criteria

Required Medical Information

All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the

prescribing information. For colorectal cancer (including appendiceal adenocarcinoma):

1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

-

Plan Year

Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group

Drug Names

HERCEPTIN HYLECTA

HERCEPTIN HYLECTA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer.

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

HERZUMA HERZUMA

All FDA-approved Indications, Some Medically-accepted Indications
Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, brain metastases from
HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction
adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous
carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including
appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer,
intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2
overexpression positive locally advanced, unresectable, or recurrent gastric
adenocarcinoma, HER2-positive endometrial cancer.

Exclusion Criteria
Required Medical Information

All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

Plan Year

Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization Group HETLIOZ

Drug Names TASIMELTEON

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For Non-24-Hour Sleep-Wake Disorder: 1) For initial therapy and continuation of

therapy the patient must meet both of the following: a) diagnosis of total blindness in both eyes (e.g., nonfunctioning retinas) and b) unable to perceive light in either eye, AND 2) If currently on therapy with the requested drug, patient must meet at least one of the following: a) increased total nighttime sleep or b) decreased daytime nap duration. For nighttime sleep disturbances in Smith-Magenis Syndrome (SMS): 1) For initial therapy and continuation therapy, the patient has a confirmed diagnosis of SMS,

AND 2) If currently on therapy with the requested drug, the patient experienced

improvement in the quality of sleep since starting therapy.

Age Restrictions Non-24: 18 years of age or older, SMS: 16 years of age or older

Prescriber Restrictions Prescribed by or in consultation with a sleep disorder specialist, neurologist, or

psychiatrist

Coverage Duration Initiation: 6 months, Renewal: Plan Year

Other Criteria -

Prior Authorization Group HRM-ANTICONVULSANTS

Drug Names PHENOBARBITAL, PHENOBARBITAL SODIUM

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Epilepsy

Exclusion Criteria -

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

outweighs the potential risks for this patient.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.

(The use of this medication is potentially inappropriate in older adults, meaning it is

best avoided, prescribed at reduced dosage, or used with caution or carefully

monitored.)

Drug Names

HRM-ANTIPARKINSON

BENZTROPINE MESYLATE, TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL

HYDROCHLO

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

All FDA-approved Indications

Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. EPS (extrapyramidal symptoms): 1) The patient has not tried the non-HRM alternative drug amantadine AND 2) The patient has a contraindication to the non-HRM alternative drug amantadine OR 3) The patient has tried the non-HRM alternative drug amantadine AND 4) The patient experienced an inadequate treatment response OR intolerance to the non-HRM alternative drug amantadine. Parkinson's: 1) The patient has tried two of the following non-HRM alternative drugs: amantadine, carbidopa/levodopa, pramipexole, or ropinirole AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following non-HRM alternative drugs: amantadine, carbidopa/levodopa,

pramipexole, or ropinirole.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

_

Plan Year

This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)

Prior Authorization Group

Drug Names

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

HRM-CYPROHEPTADINE

CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLOR

All FDA-approved Indications, Some Medically-accepted Indications

Pruritus, spasticity due to spinal cord injury

The prescriber must acknowledge that the benefit of therapy with this prescribed

medication outweighs the potential risks for this patient. For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following non-HRM alternative drugs:

levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided,

prescribed at reduced dosage, or used with caution or carefully monitored.). Prior Authorization applies to greater than cumulative 30 days of therapy per year.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group HRM-DIPYRIDAMOLE **DIPYRIDAMOLE Drug Names**

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

outweighs the potential risks for this patient.

Age Restrictions Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided,

prescribed at reduced dosage, or used with caution or carefully monitored.)

HRM-GUANFACINE ER **Prior Authorization Group**

GUANFACINE HYDROCHLORIDE Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

outweighs the potential risks for this patient.

Age Restrictions **Prescriber Restrictions**

Plan Year Coverage Duration

Other Criteria This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided,

prescribed at reduced dosage, or used with caution or carefully monitored.)

HRM-GUANFACINE IR **Prior Authorization Group**

Drug Names GUANFACINE HYDROCHLORIDE PA Indication Indicator All FDA-approved Indications

Off-label Uses

Exclusion Criteria

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

outweighs the potential risks for this patient.

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided,

prescribed at reduced dosage, or used with caution or carefully monitored.)

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

57 Updated: 10/01/2025

Drug Names

HRM-HYDROXYZINE

HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE

PAMOATE

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

All FDA-approved Indications

For anxiety: 1) The patient has tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release OR 3) The patient has not tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 4) The patient has acute anxiety. For all indications: 1)

outweighs the potential risks for this patient. AND 2) If the patient is taking one or more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, cyclobenzaprine) with the requested drug, the prescriber has determined that taking multiple anticholinergic medications is medically necessary for the patient [Note: Use of multiple anticholinergic medications in older adults is

Prescriber must acknowledge that the benefit of therapy with this prescribed medication

associated with an increased risk of cognitive decline.].

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior

authorization applies to greater than cumulative 30 days of therapy per year.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

HRM-HYDROXYZINE INJ

Drug Humoo

HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE

PA Indication Indicator

All FDA-approved Indications

Off-label Uses
Exclusion Criteria

_

Required Medical Information

Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. For alcohol withdrawal syndrome: 1) The patient has not tried one of the following alternative drugs: clorazepate or lorazepam AND 2) The patient has a contraindication to one of the following alternative drugs: clorazepate or lorazepam OR 3) The patient has tried one of the following alternative drugs: clorazepate or lorazepam AND 4) The patient experienced an inadequate treatment response OR intolerance to one of the following alternative drugs: clorazepate or lorazepam. For anxiety: 1) The patient has tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release OR 3) The patient has not tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 4) The patient has acute anxiety.

Age Restrictions
Prescriber Restrictions
Coverage Duration

-

Plan Year

Other Criteria

This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group HRM-HYPNOTICS

Drug Names ESZOPICLONE, ZALEPLON, ZOLPIDEM TARTRATE

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For insomnia: 1) The patient meets one of the following: a) the patient has a

contraindication to the non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) OR b) The non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) has been tried AND the patient experienced an inadequate treatment response OR intolerance to the non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) AND 2) Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient AND 3) If the patient is using two or more additional central nervous system (CNS) active medications (e.g., lorazepam, quetiapine, sertraline, clonazepam, escitalopram, alprazolam) with the requested drug, the prescriber has determined that taking multiple central nervous system (CNS) active medications is medically necessary for the patient [Note: Use of multiple central nervous system (CNS) active medications in older adults is associated with an increased risk of falls.].

Age Restrictions Prescriber Restrictions Coverage Duration Plan Year

Other Criteria

This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) Applies to

greater than cumulative 90 days of therapy per year.

Prior Authorization Group HRM-PROMETHAZINE

PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORID **Drug Names**

Plan Year

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

> outweighs the potential risks for this patient. For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The patient experienced an inadequate treatment

response OR intolerance to two of the following non-HRM alternative drugs:

levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal,

Age Restrictions

Prescriber Restrictions

Coverage Duration Other Criteria This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior authorization applies to greater than cumulative 30 days of therapy per year.

HRM-SCOPOLAMINE **Prior Authorization Group**

Drug Names SCOPOLAMINE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Excessive salivation

Exclusion Criteria

Required Medical Information Prescriber must acknowledge that the benefit of therapy with this prescribed medication

outweighs the potential risks for this patient.

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior authorization applies to greater than cumulative 30 days of therapy per year.

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Updated: 10/01/2025 61

Drug Names

PA Indication Indicator

Off-label Uses
Exclusion Criteria

Required Medical Information

HRM-SKELETAL MUSCLE RELAXANTS

CARISOPRODOL, CYCLOBENZAPRINE HYDROCHLO, METHOCARBAMOL

All FDA-approved Indications

-

1) Prescriber must acknowledge that the benefit of therapy with this prescribed

medication outweighs the potential risks for this patient. AND 2) If the patient is using one or more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, hydroxyzine) with the requested drug, the prescriber has determined that taking multiple anticholinergic medications is medically

necessary for the patient [Note: Use of multiple anticholinergic medications in older

adults is associated with an increased risk of cognitive decline.].

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

-

3 months

This Prior Authorization only applies to patients 70 years of age or older. (The use of

this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) Prior authorization applies to greater than cumulative 30 days of therapy per year.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

tion Group HUMIRA

Drug Names

HUMIRA, HUMIRA PEN, HUMIRA PEN-CD/UC/HS START, HUMIRA PEN-

PEDIATRIC UC S, HUMIRA PEN-PS/UV STARTER

PA Indication Indicator

All Medically-accepted Indications

Off-label Uses
Exclusion Criteria

-

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and nonradiographic axial spondyloarthritis (new starts only): patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

-

Plan Year

For non-infectious intermediate, posterior and panuveitis (new starts only): 1) patient has experienced an inadequate treatment response or intolerance to a corticosteroid OR 2) the patient has a contraindication that would prohibit a trial of corticosteroids.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group IBRANCE
Drug Names IBRANCE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Unresectable well-differentiated/dedifferentiated liposarcoma of the retroperitoneum,

recurrent hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-

negative breast cancer

Exclusion Criteria -

Required Medical Information For breast cancer: 1) the disease is advanced, recurrent, or metastatic, AND 2) the

patient has hormone receptor (HR)-positive and human epidermal growth factor

receptor 2 (HER2)-negative disease, AND 3) the patient meets ONE of the following: a)

the requested drug will be used in combination with an aromatase inhibitor or

fulvestrant AND the patient has experienced an intolerable adverse event to Kisqali (ribociclib) OR Verzenio (abemaciclib) or has a contraindication to Kisqali (ribociclib) AND Verzenio (abemaciclib), OR b) the patient is endocrine-resistant, PIK3CA-mutated, AND the requested drug will be used in combination with inavolisib and

fulvestrant.

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupIBTROZIDrug NamesIBTROZI

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ICATIBANT

Drug NamesICATIBANT ACETATE, SAJAZIR **PA Indication Indicator**All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the treatment of acute angioedema attacks due to hereditary angioedema (HAE):

1) the patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose

antihistamine therapy for at least one month.

Age Restrictions 18 years of age or older

Prescriber Restrictions Prescribed by or in consultation with an immunologist, allergist, or rheumatologist

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ICLUSIG
Drug Names ICLUSIG

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myeloid and/or lymphoid neoplasms with eosinophilia and FGFR1 or ABL1

rearrangement in the chronic phase or blast phase, Gastrointestinal Stromal Tumors

Exclusion Criteria -

Required Medical Information For chronic myeloid leukemia (CML), including patients who have received a

hematopoietic stem cell transplant: 1) Patient has accelerated or blast phase CML and no other kinase inhibitor is indicated, OR 2) Patient has chronic phase CML and has experienced resistance or intolerance to at least 2 prior kinase inhibitors AND at least one of those was imatinib, dasatinib, or nilotinib, OR 3) Patient is positive for the T315I

mutation. For acute lymphoblastic leukemia (ALL), including patients who have

received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For gastrointestinal stromal tumors

(GIST): 1) Disease meets any of the following: A) residual, B) unresectable, C)

recurrent, D) metastatic/tumor rupture, AND 2) Disease has progressed after use of at least two Food and Drug Administration (FDA) approved therapies (e.g., imatinib,

sunitinib, regorafenib, ripretinib).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Drug Names

IDACIO

ADALIMUMAB-AACF (2 PEN), ADALIMUMAB-AACF (2 SYRING, ADALIMUMAB-

AACF STARTER P, IDACIO (2 PEN), IDACIO (2 SYRINGE), IDACIO STARTER

PACKAGE FO

PA Indication Indicator

Off-label Uses **Exclusion Criteria** All Medically-accepted Indications

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and nonradiographic axial spondyloarthritis (new starts only): patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).

Age Restrictions Prescriber Restrictions **Coverage Duration** Other Criteria

Plan Year

For non-infectious intermediate, posterior and panuveitis (new starts only): 1) patient has experienced an inadequate treatment response or intolerance to a corticosteroid OR 2) the patient has a contraindication that would prohibit a trial of corticosteroids.

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Updated: 10/01/2025 66 Prior Authorization Group IDHIFA
Drug Names IDHIFA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Newly-diagnosed acute myeloid leukemia

Exclusion Criteria -

Required Medical Information For acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation:

1) patient has newly-diagnosed AML and is not a candidate for intensive induction therapy, OR 2) the requested drug will be used as post-induction therapy following response to induction therapy with the requested drug, OR 3) patient has relapsed or

refractory AML.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group IMATINIB

Drug Names IMATINIB MESYLATE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Desmoid tumors, pigmented villonodular synovitis/tenosynovial giant cell tumor

(PVNS/TGCT), recurrent chordoma, cutaneous melanoma, Kaposi sarcoma, chronic graft versus host disease (cGVHD), T-cell acute lymphoblastic leukemia with ABL-class translocation, aggressive systemic mastocytosis for well-differentiated systemic

mastocytosis (WDSM) or when eosinophilia is present with FIP1L1-PDGFRA fusion gene, myeloid and/or lymphoid neoplasms with eosinophilia and ABL1, FIP1L1-PDGFRA, or PDGFRB rearrangement in the chronic phase or blast phase.

Exclusion Criteria -

Required Medical Information For chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute

lymphoblastic leukemia (Ph+ ALL), including patients who have received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For CML: Patient did not fail (excluding failure due to intolerance) prior therapy with a tyrosine kinase inhibitor. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for c-KIT activating mutations AND 3) Requested medication will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression

with BRAF-targeted therapy.

Age Restrictions -

Prescriber Restrictions - Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group
Drug Names
PA Indication Indicator

IMBRUVICA IMBRUVICA

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications
Hairy cell leukemia, lymphoplasmacytic lymphoma, primary central nervous system
(CNS) lymphoma, human immunodeficiency virus (HIV)-related B-cell lymphoma,
diffuse large B-cell lymphoma, post-transplant lymphoproliferative disorders, high-grade
B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma (including
extranodal marginal zone lymphoma of the stomach, extranodal marginal zone
lymphoma of nongastric sites, nodal marginal zone lymphoma, splenic marginal zone
lymphoma)

Exclusion Criteria
Required Medical Information

For mantle cell lymphoma: 1) the requested drug will be used as subsequent therapy AND the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Calquence (acalabrutinib), OR 2) the requested drug will be used in combination with rituximab as pretreatment to induction therapy with RHyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen, OR 3) the requested drug will be used as aggressive induction therapy. For marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites. nodal marginal zone lymphoma, and splenic marginal zone lymphoma): the requested drug will be used as second-line or subsequent therapy. For hairy cell leukemia: the requested drug will be used as a single agent for disease progression. For primary CNS lymphoma: 1) the disease is relapsed or refractory OR 2) the requested drug is used for induction therapy as a single agent. For diffuse large B-cell lymphoma, highgrade B-cell lymphoma, human immunodeficiency virus (HIV)-related B-cell lymphoma: The requested drug will be used as a single agent and as second-line or subsequent therapy for relapsed or refractory disease. For post-transplant lymphoproliferative disorders: the requested drug will be used in patients who have received prior chemoimmunotherapy. For chronic lymphocytic leukemia/small lymphocytic lymphoma: the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Calquence (acalabrutinib).

Age Restrictions
Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization GroupIMKELDIDrug NamesIMKELDI

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent chordoma, cutaneous melanoma, Kaposi sarcoma

Exclusion Criteria -

Required Medical Information For all indications: The patient is unable to use imatinib tablets. For chronic myeloid

leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including patients who have received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For CML: Patient did not fail (excluding failure due to intolerance) prior therapy with a tyrosine kinase inhibitor. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for c-KIT activating mutations AND 3) Requested medication will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupIMPAVIDODrug NamesIMPAVIDO

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Pregnancy. Sjogren-Larsson-Syndrome.

Required Medical Information -

Age Restrictions 12 years of age or older

Prescriber Restrictions -

Coverage Duration 28 days

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupINBRIJADrug NamesINBRIJA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For initial treatment of off episodes in Parkinson's disease: 1) The patient is currently

being treated with oral carbidopa/levodopa, AND 2) The patient does not have any of the following: asthma, chronic obstructive pulmonary disease (COPD), or other chronic underlying lung disease. For continuation treatment of off episodes in Parkinson's

disease: The patient is experiencing improvement on the requested drug.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group INCRELEX
Drug Names INCRELEX

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Pediatric patients with closed epiphyses

Required Medical Information For growth failure due to severe primary insulin-like growth factor-1 (IGF-1) deficiency

or growth hormone (GH) gene deletion in patients who have developed neutralizing antibodies to GH, patient meets all of the following prior to beginning therapy with the requested drug (new starts only): 1) height 3 or more standard deviations (SD) below the mean for children of the same age and gender AND 2) basal IGF-1 level 3 or more SD below the mean for children of the same age and gender AND 3) provocative growth hormone test showing a normal or elevated growth hormone level. For growth failure due to severe primary IGF-1 deficiency or GH gene deletion in patients who have developed neutralizing antibodies to GH, continuation of therapy: patient is

experiencing improvement.

Age Restrictions 2 years of age or older

Prescriber Restrictions Prescribed by or in consultation with an endocrinologist

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group INLYTA **Drug Names** INLYTA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Thyroid carcinoma (papillary, oncocytic, or follicular), alveolar soft part sarcoma

Exclusion Criteria -

Required Medical Information For renal cell carcinoma: the disease is advanced, relapsed, or Stage IV.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupINQOVIDrug NamesINQOVI

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group INREBIC Drug Names INREBIC

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and janus kinase 2

(JAK2) rearrangement, accelerated or blast phase myeloproliferative neoplasms

Exclusion Criteria -

Required Medical Information For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and JAK2

rearrangement: the disease is in chronic or blast phase.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group INSULIN SUPPLIES

Drug Names -

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The requested product is being used with insulin.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group IR BEFORE ER

Drug Names HYDROCODONE BITARTRATE ER, METHADONE HCL, METHADONE

HYDROCHLORIDE I, MORPHINE SULFATE ER, OXYCONTIN

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information The requested drug is being prescribed for pain associated with cancer, sickle cell

disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has

taken an immediate-release opioid for at least one week.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group IRESSA GFFITINIB Drug Names

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent non-

small cell lung cancer (NSCLC)

Exclusion Criteria

Required Medical Information For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or

metastatic, AND 2) the patient must have a sensitizing epidermal growth factor receptor

(EGFR) mutation.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Prior Authorization Group

ISOTRETINOIN

Drug Names

Other Criteria

ACCUTANE, AMNESTEEM, CLARAVIS, ISOTRETINOIN, ZENATANE

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Refractory acne vulgaris, severe refractory rosacea, neuroblastoma, cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), high risk for developing

skin cancer (squamous cell cancers), transient acantholytic dermatosis (Grover's Disease), keratosis follicularis (Darier Disease), lamellar ichthyosis, pityriasis rubra

pilaris.

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization Group ITOVEBI Drug Names ITOVEBI

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria** Required Medical Information Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization Group

Drug Names

ITRACONAZOLE ITRACONAZOLE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Coccidioidomycosis, Coccidioidomycosis prophylaxis in HIV infection,, Cryptococcosis,

Microsporidiosis, Talaromycosis (formerly Penicilliosis), Histoplasmosis prophylaxis in

granulomatous disease (CGD), and hematologic malignancy, Sporotrichosis, Pityriasis

versicolor, Tinea versicolor, Tinea corporis, Tinea cruris, Tinea capitis, Tinea manuum,

Tinea pedis, primary treatment for allergic bronchopulmonary aspergillosis, primary

treatment for chronic cavitary or subacute invasive (necrotizing) pulmonary

HIV infection, Invasive fungal infection prophylaxis in liver transplant, chronic

asperaillosis

Exclusion Criteria

Required Medical Information

The requested drug will be used orally. For the treatment of onychomycosis due to

dermatophytes (Tinea unquium), the diagnosis has been confirmed by a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy). For primary treatment of allergic bronchopulmonary aspergillosis, the

requested drug is initiated in combination with systemic corticosteroids.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Disseminated/CNS histo, histo/CM/CGD ppx, chronic cavitary/necrotizing PA: 12 mths.

Others: 6 mths

IVERMECTIN TAB

Other Criteria

Prior Authorization Group

Drug Names

IVERMECTIN

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Ascariasis, Cutaneous larva migrans, Mansonelliasis, Scabies, Gnathostomiasis,

Pediculosis

Exclusion Criteria

Required Medical Information

The requested drug is not being prescribed for the prevention or treatment of

coronavirus disease 2019 (COVID-19).

Age Restrictions

Prescriber Restrictions

1 month

Coverage Duration Other Criteria

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group IVIG

Drug Names ALYGLO, BIVIGAM, FLEBOGAMMA DIF, GAMMAGARD LIQUID, GAMMAGARD S/D

IGA LESS TH, GAMMAKED, GAMMAPLEX, GAMUNEX-C, OCTAGAM, PANZYGA,

PRIVIGEN

PA Indication Indicator

Indicator All Medically-accepted Indications

Off-label Uses
Exclusion Criteria

Required Medical Information For B-cell chronic lymphocytic leukemia (CLL): 1) serum IgG less than 500 mg/dL OR

2) a history of recurrent bacterial infections. For bone marrow transplant/hematopoietic stem cell transplant (BMT/HSCT): 1) IVIG is requested within the first 100 days post-

transplant OR 2) serum IgG less than 400 mg/dL. For pediatric human

immunodeficiency virus (HIV) infection: 1) serum IgG less than 400 mg/dL OR 2) history of recurrent bacterial infections. For dermatomyositis and polymyositis: 1) at least one standard first-line treatment (corticosteroid or immunosuppressant) has been tried but was unsuccessful or not tolerated OR 2) patient is unable to receive standard therapy because of a contraindication or other clinical reason. For pure red cell aplasia

(PRCA): PRCA is secondary to parvovirus B19 infection.

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group IWILFIN

Drug Names IWILFIN

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Reguired Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

JAKAFI JAKAFI

All FDA-approved Indications, Some Medically-accepted Indications

Lower-risk myelofibrosis, accelerated or blast phase myeloproliferative neoplasms, acute lymphoblastic leukemia (ALL), chronic myelomonocytic leukemia (CMML)-2, myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with neutrophilia, essential thrombocythemia, myeloid, lymphoid or mixed lineage neoplasms with

eosinophilia and JAK2 rearrangement, T-cell prolymphocytic leukemia

Exclusion Criteria

Required Medical Information

For polycythemia vera: 1) patient had an inadequate response or intolerance to hydroxyurea and Besremi (ropeginterferon alfa-2b-njft), OR 2) patient has high risk disease. For acute lymphoblastic leukemia: patient has a cytokine receptor-like factor 2 (CRLF2) mutation or a mutation associated with activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. For CMML-2: the

requested drug is used in combination with a hypomethylating agent. For

myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with neutrophilia: the requested drug is used as a single agent or in combination with a hypomethylating agent. For essential thrombocythemia: patient had an inadequate response or loss of response to hydroxyurea, interferon therapy, or anagrelide. For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and JAK2 rearrangement: the disease is in

chronic or blast phase.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

-

Plan Year

Prior Authorization Group JAYPIRCA
Drug Names JAYPIRCA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): The patient meets both of the following: 1) The patient has received prior treatment with a Bruton Tyrosine Kinase (BTK) inhibitor, for example Calquence (acalabrutinib), AND 2) The

patient has received prior treatment with a B-cell lymphoma 2 (BCL-2) inhibitor. For mantle cell lymphoma: the patient has received prior treatment for a BTK inhibitor, for

example Calquence (acalabrutinib).

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group KALYDECO
Drug Names KALYDECO

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For cystic fibrosis (CF): The requested medication will not be used in combination with

other medications containing ivacaftor.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

PA Indication Indicator

Off-label Uses

KANJINTI KANJINTI

All FDA-approved Indications, Some Medically-accepted Indications

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer.

Exclusion Criteria

Required Medical Information

All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma):

1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent

for maintenance therapy.

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupKESIMPTADrug NamesKESIMPTA

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupKETOCONAZOLEDrug NamesKETOCONAZOLE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Cushing's syndrome

Exclusion Criteria Acute or chronic liver disease. Concurrent use with drugs that are contraindicated with

ketoconazole tablets: dofetilide, quinidine, pimozide, cisapride, methadone,

disopyramide, dronedarone, ranolazine, ergot alkaloids, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, tolvaptan, eplerenone,

lovastatin, simvastatin, or colchicine.

Required Medical Information The potential benefits outweigh the risks of treatment with oral ketoconazole. For

systemic fungal infections, the patient has any of the following diagnoses: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or

paracoccidioidomycosis. For Cushing's syndrome: the requested drug is being prescribed for a patient who cannot tolerate surgery or where surgery has not been

curative.

Age Restrictions - Prescriber Restrictions -

Coverage Duration 6 months

Other Criteria -

Prior Authorization Group KEYTRUDA Drug Names KEYTRUDA

PA Indication Indicator All Medically-accepted Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group KISQALI

Drug Names KISQALI, KISQALI FEMARA 200 DOSE, KISQALI FEMARA 400 DOSE, KISQALI

FEMARA 600 DOSE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, in combination with an aromatase inhibitor, or fulvestrant. Endometrial cancer, in combination with letrozole, for estrogen receptor

positive tumors.

Exclusion Criteria -

Required Medical Information

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group KORLYM

Drug Names MIFEPRISTONE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information - Age Restrictions -

Prescriber Restrictions Prescribed by or in consultation with an endocrinologist

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group KOSELUGO Drug Names KOSELUGO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses BRAF fusion or BRAF V600E activating mutation-positive recurrent or progressive

circumscribed glioma, Langerhans cell histiocytosis.

Exclusion Criteria -

Required Medical Information -

Age Restrictions For neurofibromatosis type 1: 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

KRAZATI KRAZATI

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent KRAS G12C-positive non-small cell lung cancer (NSCLC), Central nervous system (CNS) brain metastases from KRAS G12C-positive NSCLC, KRAS G12C-

positive pancreatic adenocarcinoma

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Coverage Duration Other Criteria

Plan Year

LAPATINIB

Prior Authorization Group

Drug Names

LAPATINIB DITOSYLATE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent HER2-positive breast cancer, recurrent epidermal growth factor receptor (EGFR)-positive chordoma, HER2-amplified and RAS and BRAF wild-

type colorectal cancer (including appendiceal adenocarcinoma).

Exclusion Criteria

Required Medical Information

For breast cancer, the patient meets all the following: a) the disease is recurrent, advanced, or metastatic (including brain metastases), b) the disease is human

epidermal growth factor receptor 2 (HER2)-positive, c) the requested drug will be used in combination with any of the following: 1) aromatase inhibitor, 2) capecitabine, OR 3) trastuzumab. For colorectal cancer: 1) requested drug will be used in combination with trastuzumab and 2) patient has not had previous treatment with a HER2 inhibitor.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

Drug Names

Prior Authorization Group

LAZCLUZE LAZCLUZE

PA Indication Indicator

All FDA-approved Indications

Off-label Uses

Exclusion Criteria

Required Medical Information Age Restrictions

Prescriber Restrictions

Coverage Duration Other Criteria

Plan Year

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group

Drug Names

LENVIMA

LENVIMA 10 MG DAILY DOSE, LENVIMA 12MG DAILY DOSE, LENVIMA 14 MG

DAILY DOSE, LENVIMA 18 MG DAILY DOSE, LENVIMA 20 MG DAILY DOSE,

LENVIMA 24 MG DAILY DOSE, LENVIMA 4 MG DAILY DOSE, LENVIMA 8 MG DAILY

DOSE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Medullary thyroid carcinoma, recurrent endometrial carcinoma, thymic carcinoma,

unresectable or metastatic cutaneous melanoma.

Exclusion Criteria

Required Medical Information

For differentiated thyroid cancer (follicular, papillary, or oncocytic): disease is not

amenable to radioactive iodine therapy and unresectable, locally recurrent, persistent, or metastatic. For hepatocellular carcinoma (HCC): disease is unresectable or inoperable, local, metastatic or with extensive liver tumor burden. For renal cell carcinoma (RCC): the disease is advanced, relapsed, or stage IV. For endometrial carcinoma (EC), the patient meets ALL of the following: 1) The disease is advanced, recurrent, or metastatic, 2) The requested drug will be used in combination with pembrolizumab, 3) The patient experienced disease progression following prior

systemic therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

LEUPROLIDE

Other Criteria

_

Prior Authorization Group

Drug Names

LEUPROLIDE ACETATE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Use in combination with growth hormone for children with growth failure and advancing puberty, recurrent androgen receptor positive salivary gland tumors, central precocious

puberty

Exclusion Criteria

Required Medical Information

For central precocious puberty (CPP): Patients not currently receiving therapy must

meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level

of a third generation luteinizing hormone (LH) assay, 2) Assessment of bone age versus chronological age supports the diagnosis of CPP, 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients OR prior to 9

years of age for male patients.

10/4/18

Age Restrictions CPP: Patient must be less than 12 years old if female and less than 13 years old if

male

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group LIDOCAINE PATCHES

Drug Names LIDOCAINE, LIDOCAN, TRIDACAINE II

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Pain associated with diabetic neuropathy, pain associated with cancer-related

neuropathy (including treatment-related neuropathy [e.g., neuropathy associated with

radiation treatment or chemotherapy]).

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group LIVTENCITY
Drug Names LIVTENCITY

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria -

Required Medical Information

Age Restrictions 12 years of age or older

Prescriber Restrictions Prescribed by or in consultation with an infectious disease specialist, transplant

specialist, hematologist, or oncologist.

Coverage Duration 3 months

Other Criteria -

Prior Authorization Group LONSURF

Drug Names LONSURF

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Unresectable locally advanced, recurrent, or metastatic esophageal cancer.

Unresectable locally advanced or recurrent gastric cancer and gastroesophageal

junction cancers. Advanced or metastatic appendiceal adenocarcinoma.

Exclusion Criteria -

Required Medical Information For colorectal cancer (including appendiceal adenocarcinoma): The disease is

advanced or metastatic. For gastric, esophageal, or gastroesophageal junction adenocarcinoma, ALL of the following criteria must be met: 1) The disease is

unresectable locally advanced, recurrent, or metastatic, and 2) The patient has been

previously treated with at least two prior lines of chemotherapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

LORBRENA LORBRENA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Anaplastic lymphoma kinase (ALK)-positive recurrent non-small cell lung cancer (NSCLC), proto-oncogene tyrosine-protein kinase ROS1 (ROS1) rearrangementpositive recurrent, advanced, or metastatic NSCLC, symptomatic or relapsed/refractory ALK-positive Erdheim-Chester Disease, inflammatory myofibroblastic tumor (IMT) with ALK translocation (including advanced, recurrent/metastatic, or inoperable uterine sarcoma for IMT with ALK translocation), central nervous system (CNS) brain metastases from ALK rearrangement-positive NSCLC, relapsed or refractory ALK-

positive Diffuse Large B-Cell Lymphoma

Exclusion Criteria

Required Medical Information

For recurrent, advanced, or metastatic non-small cell lung cancer: 1) Disease is ALKpositive AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib) OR 3) Disease is positive for ROS1 rearrangement and the requested drug is being used following disease progression on crizotinib, entrectinib, or ceritinib.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Prior Authorization Group

Drug Names

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Coverage Duration

LUMAKRAS

Plan Year

LUMAKRAS

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent KRAS G12C-positive non-small cell lung cancer (NSCLC)

Plan Year

Other Criteria

Prior Authorization GroupLUMIZYMEDrug NamesLUMIZYME

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For Pompe disease: Diagnosis was confirmed by an enzyme assay demonstrating a

deficiency of acid alpha-glucosidase (GAA) enzyme activity or by genetic testing.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group LUPRON PED

Drug Names LUPRON DEPOT-PED (1-MONTH, LUPRON DEPOT-PED (3-MONTH, LUPRON

DEPOT-PED (6-MONTH

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For central precocious puberty (CPP): Patients not currently receiving therapy must

meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay, AND 2) Assessment of bone age

versus chronological age supports the diagnosis of CPP, AND 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients

OR prior to 9 years of age for male patients.

Age Restrictions CPP: Patient must be less than 12 years old if female and less than 13 years old if

male

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

LUPRON-ENDOMETRIOSIS

LUPRON DEPOT (1-MONTH), LUPRON DEPOT (3-MONTH)

PA Indication Indicator Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications Breast cancer, ovarian cancer/fallopian tube cancer/primary peritoneal cancer,

androgen receptor positive recurrent salivary gland tumor

Exclusion Criteria

Required Medical Information

For retreatment of endometriosis, the requested drug is used in combination with

norethindrone acetate. For uterine fibroids, patient must meet one of the following: 1)

diagnosis of anemia (e.g., hematocrit less than or equal to 30 percent and/or

hemoglobin less than or equal to 10g/dL). OR 2) the requested medication will be used prior to surgery for uterine fibroids. For breast cancer, the requested drug is used for

hormone receptor (HR)-positive disease.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Fibroids: 3 months (mo), max 6 mo total. Endometriosis: 6 mo, max 12 mo total.

Others: Plan Year

Other Criteria

Prior Authorization Group

Drug Names

LYNPARZA LYNPARZA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent HER2-negative, BRCA 1/2-germline mutated breast cancer, recurrent or

metastatic HER2-positive, BRCA 1/2-germline mutated breast cancer, uterine leiomyosarcoma.

Exclusion Criteria

Required Medical Information

For recurrent or metastatic breast cancer: the disease is BRCA 1/2-germline mutated. For prostate cancer: 1) The patient has a BRCA mutation and the requested drug will be used in combination with abiraterone and an oral corticosteroid OR 2) The patient has progressed on prior treatment with an androgen receptor-directed therapy. For ovarian, fallopian tube, or primary peritoneal cancer: The requested drug is used for maintenance therapy for stage II-IV or recurrent disease who are in complete or partial response to chemotherapy. For uterine leiomyosarcoma: 1) the patient has had at least

one prior therapy AND 2) the patient has BRCA-altered disease.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

Prior Authorization GroupLYTGOBIDrug NamesLYTGOBI

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Extrahepatic cholangiocarcinoma

Exclusion Criteria -

Required Medical Information For cholangiocarcinoma: 1) patient has a diagnosis of unresectable, locally advanced

or metastatic cholangiocarcinoma, 2) patient has received a previous treatment, AND 3) patient has a disease that has a fibroblast growth factor receptor 2 (FGFR2) gene

fusion or other rearrangement.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupMAVYRETDrug NamesMAVYRET

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh

[CTP] class B or C).

Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum

prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [CTP class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases

and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance

Other Criteria -

Prior Authorization Group MEGESTROL

Drug Names MEGESTROL ACETATE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Cancer-related cachexia in adults

Exclusion Criteria -

Required Medical Information Patient has experienced an inadequate treatment response or intolerance to megestrol

40 milligrams per milliliter (40mg/mL) oral suspension.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group MEKINIST
Drug Names MEKINIST

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease.

Exclusion Criteria -

Required Medical Information For melanoma: 1) The tumor is positive for a BRAF V600 activating mutation (e.g.,

V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with dabrafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For uveal melanoma: The requested drug will be used as a single agent. For ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: The requested drug will be used to treat persistent or recurrent disease. For papillary, follicular, and oncocytic thyroid carcinoma: 1) The disease is positive for BRAF V600E mutation, AND 2) The disease is not amenable to radioactive iodine (RAI) therapy, AND 3) The requested drug will be used in combination with dabrafenib. For solid tumors: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested

drug will be used in combination with dabrafenib.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group MEKTOVI
Drug Names MEKTOVI

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Adjuvant systemic therapy for cutaneous melanoma, Langerhans Cell Histiocytosis,

recurrent non-small cell lung cancer (NSCLC)

Exclusion Criteria

Required Medical Information For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g.,

V600E or V600K), AND 2) The requested drug will be used in combination with encorafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer: 1) The tumor is positive for BRAF V600E mutation, AND 2) The requested drug will be used in combination with encorafenib, AND 3) The

disease is advanced, recurrent, or metastatic.

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

MEMANTINE

MEMANTINE HCL TITRATION P, MEMANTINE HYDROCHLORIDE, MEMANTINE

HYDROCHLORIDE E

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria This prior authorization only applies to patients less than 30 years of age.

Prior Authorization Group MEPRON

Drug Names ATOVAQUONE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Babesiosis, Toxoplasmosis, Pneumocystis jirovecii pneumonia prophylaxis in pediatric

patients, mild-to-moderate Pneumocystis jirovecii pneumonia treatment in pediatric

patients.

Exclusion Criteria -

Required Medical Information For the treatment of mild-to-moderate Pneumocystis jiroveci pneumonia (PCP): the

patient had an intolerance or has a contraindication to sulfamethoxazole/trimethoprim (SMX-TMP). For the prevention of PCP and primary toxoplasmosis prophylaxis indications: 1) the patient had an intolerance or has a contraindication to SMX-TMP, AND 2) the patient is immunocompromised. For secondary toxoplasmosis prophylaxis: the patient is immunocompromised. For babesiosis treatment: the requested drug is

used concurrently with azithromycin.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Secondary toxoplasmosis prophylaxis: 6 months, All other indications: 3 months

Other Criteria

Prior Authorization Group METHYLPHENIDATE

Drug NamesMETHYLPHENIDATE HYDROCHLOPA Indication IndicatorAll Medically-accepted Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or

Attention Deficit Disorder (ADD) OR 2) The patient has a diagnosis of narcolepsy confirmed by a sleep study OR 3) The requested drug is being prescribed for the treatment of cancer-related fatigue after other causes of fatigue have been ruled out.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupMETHYLTESTOSTERONEDrug NamesMETHYLTESTOSTERONE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or the

patient has a contraindication to alternative testosterone products (e.g., topical testosterone, transdermal testosterone, injectable testosterone). For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also

referred to as "late-onset hypogonadism") have not been established.].

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group MODAFINIL
Drug Names MODAFINIL

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Idiopathic hypersomnia

Exclusion Criteria -

Required Medical Information For excessive sleepiness associated with narcolepsy: The diagnosis has been

confirmed by sleep lab evaluation. For excessive sleepiness associated with

obstructive sleep apnea (OSA): The diagnosis has been confirmed by

polysomnography. For idiopathic hypersomnia, initial request, the diagnosis has been confirmed by ALL of the following: 1) Patient has experienced lapses into sleep or an irrepressible need to sleep during daytime, on a daily basis, for at least 3 months, AND 2) Insufficient sleep syndrome is confirmed absent, AND 3) Cataplexy is absent, AND

4) Fewer than 2 sleep onset rapid eye movement periods (SOREMPs) or no

SOREMPs, if the rapid eye movement latency on an overnight sleep study was less than or equal to 15 minutes, AND 5) Average sleep latency of less than or equal to 8 minutes on Multiple Sleep Latency Test or total 24-hour sleep time is greater than or equal to 11 hours, AND 6) Another condition (sleep disorder, medical or psychiatric disorder, or drug/medication use) does not better explain the hypersomnolence and test results. For idiopathic hypersomnia, continuation of therapy: The patient has

experienced a decrease in daytime sleepiness from baseline.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group MONJUVI

Drug Names MONJUVI

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses HIV-related B-cell lymphoma, monomorphic post-transplant lymphoproliferative

disorder (B-cell type), high-grade B-cell lymphoma

Exclusion Criteria -

Required Medical Information For diffuse large B-cell lymphoma (DLBCL) not otherwise specified, HIV-related B-cell

lymphoma, monomorphic post-transplant lymphoproliferative disorder (B-cell type), high-grade B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma: 1) the patient has relapsed or refractory disease, AND 2) the patient is not eligible for autologous stem

cell transplant (ASCT).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupMOUNJARODrug NamesMOUNJARO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupNAGLAZYMEDrug NamesNAGLAZYME

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information Diagnosis of Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) was confirmed by

an enzyme assay demonstrating a deficiency of N-acetylgalactosamine 4-sulfatase

(arylsulfatase B) enzyme activity or by genetic testing.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group NERLYNX
Drug Names NERLYNX

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer,

brain metastases from HER2-positive breast cancer.

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

SORAFENIB TOSYLATE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications Acute myeloid leukemia, soft tissue sarcoma (angiosarcoma, desmoid

tumors/aggressive fibromatosis, and solitary fibrous tumor subtypes), gastrointestinal stromal tumor, medullary thyroid carcinoma, osteosarcoma, recurrent chordoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, lymphoid and/or myeloid neoplasms with eosinophilia and FLT3 rearrangement in chronic or

blast phase

NEXAVAR

Exclusion Criteria

Required Medical Information

For acute myeloid leukemia: the disease is FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation-positive and any of the following is met :1) the requested drug will be used as maintenance therapy after hematopoietic stem cell transplant, OR 2) the requested drug is being used for low-intensity treatment induction, post-induction therapy, or consolidation therapy, OR 3) the disease is relapsed/refractory. For thyroid carcinoma: histology is follicular, papillary, oncocytic, or medullary. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture, AND 2) the disease has progressed after use of at least two FDA-approved therapies (e.g., imatinib, sunitinib,

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group NINLARO

Drug Names NINLARO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

regorafenib, ripretinib).

Off-label Uses Relapsed/refractory systemic light chain amyloidosis, Waldenstrom macroglobulinemia,

lymphoplasmacytic lymphoma

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupNITISINONEDrug NamesNITISINONE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hereditary tyrosinemia type 1 (HT-1): Diagnosis of HT-1 is confirmed by one of the

following: 1) biochemical testing (e.g., detection of succinylacetone in urine) OR 2)

DNA testing (mutation analysis).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupNORTHERADrug NamesDROXIDOPA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For neurogenic orthostatic hypotension (nOH): For initial therapy, patient has a

persistent, consistent decrease in systolic blood pressure of at least 20 mmHg OR decrease in diastolic blood pressure of at least 10 mmHg within 3 minutes of standing or head-up tilt test. For continuation of therapy, patient has experienced a sustained reduction in symptoms of nOH (i.e., decrease in dizziness, lightheadedness, or feeling faint). For both initial and continuation of therapy, the requested drug will be used for patients with neurogenic orthostatic hypotension associated with one of the following diagnoses: 1) primary autonomic failure due to Parkinson's disease, multiple system atrophy, or pure autonomic failure, OR 2) dopamine beta-hydroxylase deficiency, OR 3)

non-diabetic autonomic neuropathy.

Age Restrictions Prescriber Restrictions -

Coverage Duration 3 months

Other Criteria -

Prior Authorization GroupNOXAFIL SUSPDrug NamesPOSACONAZOLE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The requested drug will be used orally. For treatment of oropharyngeal candidiasis:

patient has experienced an inadequate treatment response, intolerance, or has a

contraindication to fluconazole.

Age Restrictions 13 years of age or older

Prescriber Restrictions -

Coverage Duration Oropharyngeal candidiasis: 1 month. All other indications: 6 months

Other Criteria -

Prior Authorization GroupNUBEQADrug NamesNUBEQA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone

(GnRH) analog or after bilateral orchiectomy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupNUEDEXTADrug NamesNUEDEXTA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For pseudobulbar affect (PBA) (continuation): The patient has experienced a decrease

in pseudobulbar affect (PBA) episodes since starting therapy with the requested drug.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Initial: 4 months, Continuation: Plan Year

Other Criteria -

Prior Authorization GroupNUPLAZIDDrug NamesNUPLAZID

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hallucinations and delusions associated with Parkinson's disease psychosis, the

diagnosis of Parkinson's disease must be made prior to the onset of psychotic

symptoms.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group NURTEC Drug Names NURTEC

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information Acute migraine treatment: The patient has experienced an inadequate treatment

response, intolerance, or the patient has a contraindication to one triptan 5-HT1 receptor agonist. Preventive treatment of migraine, continuation: The patient received at least 3 months of treatment with the requested drug and had a reduction in migraine

days per month from baseline.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Preventive treatment of migraine, initial: 3 months, All other indications: Plan Year

Other Criteria -

Prior Authorization Group OCTREOTIDE

Drug Names OCTREOTIDE ACETATE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Tumor control of thymomas and thymic carcinomas

Exclusion Criteria -

Required Medical Information For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1

(IGF-1) level for age and/or gender based on the laboratory reference range AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly,

continuation of therapy: Patient's IGF-1 level has decreased or normalized since

initiation of therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupODOMZODrug NamesODOMZO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupOFEVDrug NamesOFEV

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For idiopathic pulmonary fibrosis (new starts only): 1) a high-resolution computed

tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial pneumonia (UIP) pattern, OR 2) HRCT study of the chest reveals a result other than the UIP pattern (e.g., probable UIP, indeterminate for UIP) and the diagnosis is supported either by a lung biopsy or by a multidisciplinary discussion between at least a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if

a lung biopsy has not been conducted.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

OGIVRI OGIVRI

All FDA-approved Indications, Some Medically-accepted Indications

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer.

Exclusion Criteria

Required Medical Information

All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma):

1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent

for maintenance therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization GroupOGSIVEODrug NamesOGSIVEO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group OJEMDA
Drug Names OJEMDA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For relapsed or refractory pediatric low-grade glioma (LGG): the patient's tumor is

positive for either a) BRAF fusion or rearrangement OR b) BRAF V600 mutation.

Age Restrictions -Prescriber Restrictions --

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupOJJAARADrug NamesOJJAARA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Accelerated or blast phase myeloproliferative neoplasms

Exclusion Criteria -

Required Medical Information For myelofibrosis, patient meets ALL of the following: 1) the patient has a diagnosis of

intermediate or high-risk primary myelofibrosis or secondary myelofibrosis (i.e., post-polycythemia vera or post-essential thrombocythemia), AND 2) the patient has anemia defined as hemoglobin less than 10 grams per deciliter (g/dL) or having transfusion-dependent anemia, AND 3) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Jakafi (ruxolitinib) OR has

hemoglobin less than 8 g/dL.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group OMEGA-3

Drug NamesOMEGA-3-ACID ETHYL ESTERSPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hypertriglyceridemia: Prior to the start of treatment with a triglyceride lowering drug,

the patient has/had a pretreatment triglyceride level greater than or equal to 500

milligram per deciliter (mg/dL).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

OMNIPOD

OMNIPOD 5 DEXCOM G7G6 INT, OMNIPOD 5 DEXCOM G7G6 POD, OMNIPOD 5

G7 INTRO KIT (G, OMNIPOD 5 G7 PODS (GEN 5), OMNIPOD 5 LIBRE2 PLUS G6, OMNIPOD CLASSIC PODS (GEN, OMNIPOD DASH INTRO KIT (G, OMNIPOD DASH

PODS (GEN 4)

PA Indication Indicator

All FDA-approved Indications

Off-label Uses

Exclusion Criteria

Required Medical Information

Initial: 1) The patient has diabetes requiring insulin management with multiple daily injections AND 2) The patient is self-testing glucose levels 4 or more times per day OR the patient is using a continuous glucose monitor AND 3) The patient has experienced any of the following with the current diabetes regimen: inadequate glycemic control, recurrent hypoglycemia, wide fluctuations in blood glucose, dawn phenomenon with persistent severe early morning hyperglycemia, severe glycemic excursions.

Age Restrictions

Prescriber Restrictions

Plan Year

Coverage Duration Other Criteria

Prior Authorization Group

Drug Names

OMNIPOD GO

OMNIPOD GO 10 UNITS/DAY, OMNIPOD GO 15 UNITS/DAY, OMNIPOD GO 20

UNITS/DAY, OMNIPOD GO 25 UNITS/DAY, OMNIPOD GO 30 UNITS/DAY.

OMNIPOD GO 35 UNITS/DAY. OMNIPOD GO 40 UNITS/DAY

PA Indication Indicator

All FDA-approved Indications

Exclusion Criteria

Off-label Uses

Required Medical Information

Initial: 1) the patient has diabetes requiring insulin management AND 2) the patient is currently self-testing glucose levels, the patient will be counseled on self-testing

glucose levels, or the patient is using a continuous glucose monitor AND 3) the patient has experienced an inadequate treatment response or intolerance to long-acting basal

insulin therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

ONTRUZANT ONTRUZANT

All FDA-approved Indications, Some Medically-accepted Indications

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer.

Exclusion Criteria

Required Medical Information

All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the

prescribing information. For colorectal cancer (including appendiceal adenocarcinoma):

1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria Coverage

Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group ONUREG
Drug Names ONUREG

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Peripheral T-cell lymphoma

Exclusion Criteria - Required Medical Information -

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupOPIPZADrug NamesOPIPZA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For treatment of schizophrenia, 1) the patient meets both of the following: a) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND b) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar, OR 2) The patient is unable to swallow oral formulations. For adjunctive treatment of major depressive disorder (MDD), 1) the patient meets both of the following: a) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, olanzapine, quetiapine, AND b) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Rexulti, Vraylar, OR 2) The patient is unable to swallow oral formulations. For treatment of irritability associated with autistic disorder: 1) The patient experienced an inadequate treatment response. intolerance, or has a contraindication to one of the following generic products: aripiprazole, risperidone, OR 2) The patient is unable to swallow oral formulations. For the treatment of Tourette's disorder: 1) The patient experienced an inadequate treatment response or intolerance to generic aripiprazole, OR 2) The patient is unable to swallow oral formulations.

Age Restrictions --

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization GroupOPSUMITDrug NamesOPSUMIT

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group

1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood

units.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupORGOVYXDrug NamesORGOVYX

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ORKAMBI
Drug Names ORKAMBI

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For cystic fibrosis (CF): The requested medication will not be used in combination with

other medications containing ivacaftor.

Age Restrictions 1 year of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ORSERDU Drug Names ORSERDU

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent hormone receptor positive, human epidermal growth factor receptor 2

(HER2)-negative breast cancer

Exclusion Criteria -

Required Medical Information Breast cancer: 1) the disease is estrogen receptor (ER) positive, human epidermal

growth factor receptor 2 (HER2)-negative, and ESR1 mutated AND 2) the patient meets either of the following: a) the disease is advanced, recurrent, or metastatic AND the patient has disease progression following at least one line of endocrine therapy OR

b) the disease had no response to preoperative systemic therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupOZEMPICDrug NamesOZEMPIC

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group PANRETIN
Drug Names PANRETIN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Topical treatment of cutaneous lesions in patients with non-AIDS-related Kaposi

sarcoma

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group PAROXETINE SUSP

Drug Names PAROXETINE HYDROCHLORIDE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information The patient has difficulty swallowing solid oral dosage forms (e.g., capsules, tablets).

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupPEGASYSDrug NamesPEGASYS

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myeloproliferative neoplasm (essential thrombocythemia, polycythemia vera,

symptomatic lower-risk myelofibrosis), systemic mastocytosis, adult T-cell

leukemia/lymphoma, mycosis fungoides/sezary syndrome, primary cutaneous CD30+ T-cell lymphoproliferative disorders, hairy cell leukemia, Erdheim-Chester disease,

initial treatment during pregnancy for chronic myeloid leukemia.

Exclusion Criteria

Required Medical Information For chronic hepatitis C: Hepatitis C virus (HCV) confirmed by presence of hepatitis C

virus HCV RNA in serum prior to starting treatment and the planned treatment regimen.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration HCV: 12-48wks. HBV: 48wks. Other: Plan Yr

Other Criteria -

Prior Authorization GroupPEMAZYREDrug NamesPEMAZYRE

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group PHENYLBUTYRATE

Drug NamesSODIUM PHENYLBUTYRATEPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For urea cycle disorders (UCD): Diagnosis of UCD was confirmed by enzymatic,

biochemical, or genetic testing.

Age Restrictions --

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupPHESGODrug NamesPHESGO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer

Exclusion Criteria -

Required Medical Information

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupPIMECROLIMUSDrug NamesPIMECROLIMUS

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Psoriasis on the face, genitals, or skin folds.

Exclusion Criteria -

Required Medical Information For mild to moderate atopic dermatitis (eczema): the patient meets either of the

following criteria: 1) the disease affects sensitive skin areas (e.g., face, genitals, or skin

folds), OR 2) the patient has experienced an inadequate treatment response,

intolerance, or contraindication to at least one first line therapy agent (e.g., medium or

higher potency topical corticosteroid). For all indications: the requested drug is

prescribed for short-term or non-continuous chronic use.

Age Restrictions 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group PIQRAY

PIQRAY 200MG DAILY DOSE, PIQRAY 250MG DAILY DOSE, PIQRAY 300MG **Drug Names**

DAILY DOSE

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2

(HER2)-negative, PIK3CA-mutated breast cancer in combination with fulvestrant.

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Plan Year Coverage Duration

Other Criteria

Prior Authorization Group POMALYST Drug Names POMALYST

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Relapsed/refractory systemic light chain amyloidosis, primary central nervous system

(CNS) lymphoma, POEMS (polyneuropathy, organomegaly, endocrinopathy,

monoclonal protein, skin changes) syndrome

Exclusion Criteria

Required Medical Information For multiple myeloma, patient has previously received at least two prior therapies,

including an immunomodulatory agent AND a proteasome inhibitor.

Age Restrictions

Prescriber Restrictions

Plan Year **Coverage Duration**

Other Criteria

POSACONAZOLE Prior Authorization Group POSACONAZOLE DR **Drug Names**

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

Required Medical Information The requested drug will be used orally. For prophylaxis of invasive Aspergillus and

Candida infections: patient weighs greater than 40 kilograms.

Age Restrictions Treatment of Invasive Aspergillosis: 13 years of age or older, Prophylaxis of Invasive

Aspergillus and Candida Infections: 2 years of age or older

Prescriber Restrictions

Coverage Duration 6 months

Other Criteria

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization GroupPREGABALINDrug NamesPREGABALIN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Cancer-related neuropathic pain, cancer treatment-related neuropathic pain

Exclusion Criteria -

Required Medical Information For the management of postherpetic neuralgia, the management of neuropathic pain

associated with diabetic peripheral neuropathy: The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to gabapentin.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupPREVYMISDrug NamesPREVYMIS

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For prophylaxis of cytomegalovirus (CMV) infection or disease in hematopoietic stem

cell transplant (HSCT): 1) the patient is CMV-seropositive, AND 2) the patient is a recipient of an allogeneic HSCT. For prophylaxis of CMV disease in kidney transplant: 1) the patient is CMV-seronegative, AND 2) the patient is a high risk recipient of kidney

transplant.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 7 months

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

PROCRIT PROCRIT

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Anemia due to myelodysplastic syndromes (MDS), anemia in rheumatoid arthritis (RA), anemia due to hepatitis C treatment (ribavirin in combination with either interferon alfa

or peginterferon alfa)

Exclusion Criteria

Required Medical Information

Patients receiving chemotherapy with curative intent. Patients with myeloid cancer. Requirements regarding hemoglobin (Hgb) values exclude values due to a recent transfusion. For initial approval: 1) for all uses except anemia due to chemotherapy or

transfusion. For initial approval: 1) for all uses except anemia due to chemotherapy or myelodysplastic syndrome (MDS): patient has adequate iron stores (for example, a transferrin saturation [TSAT] greater than or equal to 20%), AND 2) for all uses except surgery: pretreatment (no erythropoietin treatment in previous month) Hgb is less than 10 g/dL, AND 3) for MDS: pretreatment serum erythropoietin level is 500 international units/L or less. For reauthorizations (patient received erythropoietin treatment in previous month) in all uses except surgery: 1) patient has received at least 12 weeks of erythropoietin therapy, AND 2) patient responded to erythropoietin therapy, AND 3)

current Hgb is less than 12 g/dL, AND 4) for all uses except anemia due to

chemotherapy or MDS: patient has adequate iron stores (for example, a transferring

saturation [TSAT] greater than or equal to 20%).

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

16 weeks

Coverage includes use in anemia in patients whose religious beliefs forbid blood

transfusions. Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual (e.g., used for treatment of anemia for a patient with chronic renal failure who is undergoing dialysis, or furnished from physician's supply incident to a physician

service).

Prior Authorization Group

Drug Names

PULMOZYME

PULMOZYME

PA Indication Indicator

All FDA-approved Indications

Off-label Uses

-

Exclusion Criteria

-

Required Medical Information

-

Age Restrictions

Prescriber Restrictions
Coverage Duration

Plan Year

Other Criteria

Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group PYZCHIVA - PENDING CMS REVIEW

Drug Names PYZCHIVA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body

surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, scalp, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin,

intertriginous areas] are affected).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group QINLOCK
Drug Names QINLOCK

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label UsesGastrointestinal stromal tumor (GIST) for residual, unresectable, tumor rupture, recurrent, or progressive disease. Metastatic or unresectable cutaneous melanoma.

Exclusion Criteria -

Required Medical Information For residual, unresectable, tumor rupture, advanced, recurrent/metastatic, or

progressive gastrointestinal stromal tumor (GIST): 1) Patient has received prior treatment with 3 or more kinase inhibitors, including imatinib OR 2) Patient has experienced disease progression following treatment with avapritinib and dasatinib OR 3) Patient has received prior treatment with imatinib and is intolerant of second-line sunitinib. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for KIT activating mutations AND 3) Requested drug will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of

progression with BRAF-targeted therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Drug Names

QUETIAPINE FUMARATE ER

QUETIAPINE XR

PA Indication Indicator

Off-label Uses

Exclusion Criteria

All FDA-approved Indications, Some Medically-accepted Indications

Maintenance monotherapy treatment in bipolar I disorder, monotherapy treatment of generalized anxiety disorder, monotherapy treatment of major depressive disorder

Required Medical Information

For all indications: If the patient is 65 years of age or older AND is using two or more additional central nervous system (CNS) active medications (e.g., lorazepam, sertraline, clonazepam, escitalopram, alprazolam, zolpidem) with the requested drug, the prescriber determined that taking multiple central nervous system (CNS) active medications is medically necessary. [Note: Use of multiple central nervous system (CNS) active medications in older adults is associated with an increased risk of falls]. For treatment of schizophrenia: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine immediate-release, risperidone, ziprasidone. For acute treatment of manic or mixed episodes associated with bipolar I disorder or maintenance treatment of bipolar I disorder: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: aripiprazole, asenapine, olanzapine, quetiapine immediate-release, risperidone, ziprasidone. For acute treatment of depressive episodes associated with bipolar I disorder: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: lurasidone, olanzapine, quetiapine immediate-release. For acute treatment of depressive episodes associated with bipolar II disorder: The patient experienced an inadequate treatment response or intolerance to generic quetiapine immediate-release. For adjunctive treatment of major depressive disorder (MDD): The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the

following generic products: aripiprazole, olanzapine, quetiapine immediate-release.

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization Group

Drug Names

Off-label Uses

QUININE SULFATE

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Babesiosis, uncomplicated Plasmodium vivax malaria.

Exclusion Criteria

Required Medical Information

For babesiosis: the requested drug is used in combination with clindamycin.

Age Restrictions **Prescriber Restrictions**

QUININE SULFATE

Coverage Duration 1 month

Other Criteria

Prior Authorization GroupQULIPTADrug NamesQULIPTA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information Preventive treatment of migraine, continuation: The patient received at least 3 months

of treatment with the requested drug and had a reduction in migraine days per month

from baseline.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Initial: 3 months, Continuation: Plan Year

Other Criteria -

Prior Authorization GroupRALDESYDrug NamesRALDESY

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Denvised Medical Information — The

Required Medical Information The patient is unable to swallow trazodone tablets.

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupRELISTOR INJDrug NamesRELISTOR

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the treatment of opioid-induced constipation in a patient with chronic non-cancer

pain, including chronic pain related to prior cancer or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation: 1) the patient is unable to tolerate oral medications, OR 2) the patient meets one of the following criteria: A) experienced an inadequate treatment response or intolerance to an oral drug indicated for opioid-induced constipation in a patient with chronic non-cancer pain (e.g., Movantik), OR B) the patient has a contraindication that would prohibit a trial of an oral drug indicated for opioid-induced constipation in a patient with chronic non-cancer pain (e.g., Movantik).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 4 months

Other Criteria -

Drug Names

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

REMICADE

INFLIXIMAB, REMICADE

All FDA-approved Indications, Some Medically-accepted Indications

Behcet's syndrome, hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma

gangrenosum, sarcoidosis, Takayasu's arteritis, uveitis.

_

For moderately to severely active rheumatoid arthritis (new starts only): 1) Pt meets ANY of the following: a) requested drug will be used in combination with methotrexate (MTX) or leflunomide OR b) intolerance or contraindication to MTX AND leflunomide, AND 2) Pt meets ANY of the following: a) inadequate treatment response, intolerance or contraindication to MTX OR b) inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis (new starts only): an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR contraindication that would prohibit a trial of NSAIDs. For moderate to severe plague psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at time of diagnosis, AND 2) Pt meets ANY of the following: a) Pt has experienced inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b) pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c) Pt has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

-

Plan Year

For hidradenitis suppurativa (new starts only): Pt has severe, refractory disease. For uveitis (new starts only): Inadequate treatment response or intolerance or has a contraindication to a trial of immunosuppressive therapy for uveitis. For all indications: The patient experienced an intolerable adverse event to Renflexis and that adverse event was NOT attributed to the active ingredient as described in the prescribing information

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

RENFLEXIS RENFLEXIS

All FDA-approved Indications, Some Medically-accepted Indications

Behcet's syndrome, hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma

gangrenosum, sarcoidosis, Takayasu's arteritis, uveitis

Exclusion Criteria

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): 1) Pt meets
ANY of the following: a) requested drug will be used in combination with methotrexate

(MTX) or left uportion OR b) intolerance or controlled in the MTX AND left uportion.

(MTX) or leflunomide OR b) intolerance or contraindication to MTX AND leflunomide, AND 2) Pt meets ANY of the following: a) inadequate treatment response, intolerance or contraindication to MTX OR b) inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis (new starts only): an inadequate treatment

response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque

psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at time of diagnosis. AND 2) Pt meets ANY of the following: a) Pt has

experienced inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b) pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c)

Pt has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin,

intertriginous areas] are affected).

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

For hidradenitis suppurativa (new starts only): Pt has severe, refractory disease. For

uveitis (new starts only): Inadequate treatment response or intolerance or has a

contraindication to a trial of immunosuppressive therapy for uveitis.

Prior Authorization Group REPATHA

Drug Names REPATHA, REPATHA PUSHTRONEX SYSTEM, REPATHA SURECLICK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information -

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group RETEVMO
Drug Names RETEVMO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Recurrent rearranged during transfection (RET)-rearrangement positive non-small cell lung cancer (NSCLC), brain metastases from RET fusion-positive NSCLC, Langerhans Cell Histiocytosis with a RET gene fusion, symptomatic or relapsed/refractory Erdheim-Chester Disease with a RET gene fusion, symptomatic or relapsed/refractory Rosai-Dorfman Disease with a RET gene fusion, occult primary cancer with RET gene fusion,

solid tumors with RET-gene fusion for recurrent disease

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC), patient must meet all of the following: 1) The

disease is recurrent, advanced or metastatic, AND 2) The tumor is rearranged during transfection (RET) fusion-positive or RET rearrangement positive. For solid tumors, patient must meet all of the following: 1) The disease is recurrent, persistent, progressive, unresectable, locally advanced, or metastatic, 2) The patient has

progressed on or following prior systemic treatment or has no satisfactory alternative treatment options, AND 3) The tumor is RET fusion-positive.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

LENALIDOMIDE

REVLIMID

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Systemic light chain amyloidosis, classical Hodgkin lymphoma, myelodysplastic syndrome without the 5q deletion cytogenetic abnormality, myelofibrosis-associated anemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, myeloproliferative neoplasms, Kaposi Sarcoma, Langerhans cell histiocytosis, Rosai-Dorfman disease, peripheral T-Cell lymphomas not otherwise specified, angioimmunoblastic T-cell lymphoma (AITL), enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, primary central nervous system (CNS) lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), human immunodeficiency virus (HIV)-related B-cell lymphomas, monomorphic post-transplant lymphoproliferative disorder, diffuse large B-cell lymphoma, multicentric Castlemans disease, high-grade B-cell lymphomas, histologic transformation of indolent lymphoma to diffuse large B-cell lymphoma

Exclusion Criteria

Required Medical Information

For myelodysplastic syndrome (MDS): patient has lower risk MDS with symptomatic

anemia per the Revised International Prognostic Scoring System (IPSS-R),

International Prognostic Scoring System (IPSS), or World Health organization (WHO)

classification-based Prognostic Scoring System (WPSS).

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

....

Prior Authorization Group REVUFORJ

Drug Names REVUFORJ

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information - Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupREZLIDHIADrug NamesREZLIDHIA

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupREZUROCKDrug NamesREZUROCK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Required Medical Information -

Age Restrictions 12 years of age or older

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Drug Names

RINVOQ, RINVOQ LQ

PA Indication Indicator

All FDA-approved Indications

Off-label Uses

RINVOQ

Exclusion Criteria

_

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For active psoriatic arthritis (new starts only): Patient has experienced an inadequate treatment response. intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumabaacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active ulcerative colitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active Crohn's disease (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumab-aacf]). For atopic dermatitis (new starts only): 1) Patient has refractory, moderate to severe disease, AND 2) Patient has had an inadequate response to treatment with at least one other systemic drug product, including biologics, or use of these therapies are inadvisable. For atopic dermatitis (continuation of therapy): Patient achieved or maintained positive clinical response. For active ankylosing spondylitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For non-radiographic axial spondyloarthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor.

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

Atopic dermatitis: 12 years of age or older

Atopic dermatitis (initial): 4 months, All others: Plan Year

For active polyarticular juvenile idiopathic arthritis (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]).

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupROMVIMZADrug NamesROMVIMZA

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupROZLYTREKDrug NamesROZLYTREK

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent ROS1-positive non-small cell lung cancer (NSCLC), Non-metastatic

neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors, first-line treatment of NTRK gene fusion-positive solid tumors, ROS1-gene fusion-positive

cutaneous melanoma

Exclusion Criteria -

Required Medical Information For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors:

the disease is without a known acquired resistance mutation. For ROS1-positive non-small cell lung cancer: the patient has recurrent, advanced, or metastatic disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupRUBRACADrug NamesRUBRACA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Uterine leiomyosarcoma, pancreatic adenocarcinoma, advanced (stage II-IV) epithelial

ovarian, fallopian tube, or primary peritoneal cancer

Exclusion Criteria -

Required Medical Information For metastatic castration-resistant prostate cancer with a deleterious breast cancer

susceptibility gene (BRCA) mutation (germline and/or somatic): 1) patient has been treated with androgen receptor-directed therapy, AND 2) patient has been treated with a taxane-based chemotherapy or the patient is not fit for chemotherapy, AND 3) the requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy. For maintenance treatment of BRCA mutated ovarian, fallopian tube, primary peritoneal cancer: 1) the patient has advanced (stage II-IV) disease and is in complete or partial response to primary therapy, OR 2) the patient has recurrent disease and is in complete or partial response to platinum-based chemotherapy. For uterine leiomyosarcoma: 1) the requested drug is used as second-line therapy, AND 2) the patient has BRCA-altered disease. For pancreatic adenocarcinoma: 1) the patient has metastatic disease, AND 2) the patient has somatic

or germline BRCA or PALB-2 mutations.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupRYBELSUSDrug NamesRYBELSUS

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group RYDAPT Drug Names RYDAPT

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Relapsed or refractory acute myeloid leukemia (AML), myeloid, lymphoid, or mixed

lineage neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements, post-

induction therapy for AML, re-induction in residual disease for AML

Exclusion Criteria -

Required Medical Information For acute myeloid leukemia (AML): AML is FMS-like tyrosine kinase 3 (FLT3) mutation-

positive. For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and Fibroblast growth factor receptor type 1 (FGFR1) or FLT3 rearrangements: the disease

is in chronic or blast phase.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group SAPROPTERIN

Drug Names JAVYGTOR, SAPROPTERIN DIHYDROCHLORI

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For phenylketonuria (PKU): For patients who have not yet received a therapeutic trial of

the requested drug, the patient's pretreatment (including before dietary management)

phenylalanine level is greater than 6 mg/dL (360 micromol/L). For patients who

completed a therapeutic trial of the requested drug, the patient must have experienced

improvement (e.g., reduction in blood phenylalanine levels, improvement in

neuropsychiatric symptoms).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Initial: 2 months, All others: Plan Year

Other Criteria -

Updated: 10/01/2025 121

Prior Authorization Group SCEMBLIX Drug Names SCEMBLIX

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in

chronic phase or blast phase.

Exclusion Criteria

Required Medical Information For chronic myeloid leukemia (CML) in the chronic phase: 1) Diagnosis was confirmed

by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) Patient meets

one of the following: A) Patient has newly diagnosed CML and has resistance or intolerance to imatinib, dasatinib, or nilotinib OR B) Patient has previously treated CML AND at least one of the prior treatments was imatinib, dasatinib, or nilotinib OR C) Patient is positive for the T315I mutation, AND 3) Patient is negative for the following

mutations: A337T, P465S.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupSIGNIFORDrug NamesSIGNIFOR

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions -

Prescriber Restrictions Prescribed by or in consultation with an endocrinologist

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group SILDENAFIL

Drug Names SILDENAFIL CITRATE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group

1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) If the request is for an adult, pretreatment pulmonary vascular resistance is

greater than or equal to 3 Wood units.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupSIRTURODrug NamesSIRTURO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions -

Prescriber Restrictions Prescribed by or in consultation with an infectious disease specialist

Coverage Duration Plan Year

Other Criteria -

Updated: 10/01/2025 123

Prior Authorization Group SKYRIZI

Drug Names SKYRIZI, SKYRIZI PEN

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body

surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group SOMATULINE DEPOT

Drug NamesLANREOTIDE ACETATE, SOMATULINE DEPOT

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Tumor control of neuroendocrine tumors (NETs) (including tumors of the lung, thymus, well-differentiated grade 3 NETs not of gastroenteropancreatic origin with favorable

biology, and pheochromocytoma/paraganglioma)

Exclusion Criteria -

Required Medical Information For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1

(IGF-1) level for age and/or gender based on the laboratory reference range, AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly,

continuation of therapy: Patient's IGF-1 level has decreased or normalized since

initiation of therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupSOMAVERTDrug NamesSOMAVERT

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1

(IGF-1) level for age and/or gender based on the laboratory reference range, AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly, continuation of therapy: Patient's IGF-1 level has decreased or normalized since

initiation of therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupSOTYKTUDrug NamesSOTYKTU

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body

surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous

areas] are affected).

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Updated: 10/01/2025 125

Prior Authorization Group
Drug Names

PA Indication Indicator

Off-label Uses

DASATINIB

SPRYCEL

All FDA-approved Indications, Some Medically-accepted Indications

Gastrointestinal stromal tumor (GIST), metastatic and/or widespread chondrosarcoma, recurrent chordoma, T-cell acute lymphoblastic leukemia (ALL), and Philadelphia (Ph)-

like B-ALL, myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase, cutaneous melanoma

Exclusion Criteria

Required Medical Information

For chronic myeloid leukemia (CML), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia (Ph) chromosome or BCR-ABL gene AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I/A, F317L/V/I/C, and V299L. For acute lymphoblastic leukemia (ALL), the patient has a diagnosis of one of the following: 1) Philadelphia chromosome positive ALL, including patients who have received a hematopoietic stem cell transplant: Diagnosis that has been confirmed by detection of the Ph chromosome or BCR-ABL gene AND if patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I/A, F317L/V/I/C, and V299L OR 2) Ph-like B-ALL with ABL-class kinase fusion OR 3) Relapsed or refractory T-cell ALL with ABL-class translocation. For gastrointestinal stromal tumor (GIST): 1) Patient meets all of the following: A) Disease is residual, unresectable, recurrent/progressive, or metastatic/tumor rupture, B) Patient has received prior therapy with avapritinib AND C) Patient is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations. For cutaneous melanoma: 1) Disease is metastatic or unresectable, 2) Disease is positive for c-KIT activating mutations AND 3) Requested drug will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

therapy.

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization GroupSTELARADrug NamesSTELARA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body

surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous

areas] are affected).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group STIVARGA Drug Names STIVARGA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Osteosarcoma, glioblastoma, angiosarcoma, retroperitoneal/intra-abdominal soft tissue sarcoma, rhabdomyosarcoma, soft tissue sarcomas of the extremities, body wall, head

and neck, appendiceal adenocarcinoma

Exclusion Criteria -

Required Medical Information

For colorectal cancer: 1) The disease is advanced or metastatic, AND 2) The patient

has experienced an inadequate treatment response, intolerance, or has a

contraindication to Lonsurf (trifluridine/tipiracil).

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group SUTENT

Drug Names SUNITINIB MALATE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Thyroid carcinoma (follicular, medullary, papillary, and oncocytic), soft tissue sarcoma

(angiosarcoma, solitary fibrous tumor, and alveolar soft part sarcoma subtypes), recurrent chordoma, thymic carcinoma, lymphoid and/or myeloid neoplasms with eosinophilia and FLT3 rearrangement in chronic or blast phase, pheochromocytoma,

paraganglioma, well differentiated grade 3 neuroendocrine tumors

Exclusion Criteria -

Required Medical Information For renal cell carcinoma (RCC): 1) The disease is relapsed, advanced, or stage IV OR

2) the requested drug is being used as adjuvant treatment for patients that are at high

risk of recurrent RCC following nephrectomy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group SYMDEKO
Drug Names SYMDEKO

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For cystic fibrosis: The requested medication will not be used in combination with other

medications containing ivacaftor.

Age Restrictions 6 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupSYMPAZANDrug NamesSYMPAZAN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Seizures associated with Dravet syndrome

Exclusion Criteria -

Required Medical Information -

Age Restrictions Seizures associated with Lennox-Gastaut syndrome (LGS): 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group SYNAREL Drug Names SYNAREL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For central precocious puberty (CPP): Patients not currently receiving therapy must

meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay, AND 2) Assessment of bone age versus chronological age supports the diagnosis of CPP, AND 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients OR prior to 9 years of age for male patients. For management of endometriosis: Patient has not already received greater than or equal to 6 months of treatment with the

requested drug.

Age Restrictions CPP: Patient must be less than 12 years of age if female and less than 13 years of age

if male, Endometriosis: 18 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TABRECTA
Drug Names TABRECTA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level mesenchymal-

epithelial transition (MET) amplification, central nervous system (CNS) brain

metastases from MET exon-14 mutated NSCLC

Exclusion Criteria -

Required Medical Information For recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC): Tumor is

positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutation.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group TADALAFIL (BPH)

Drug Names TADALAFIL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Erectile Dysfunction.

Required Medical Information For benign prostatic hyperplasia (BPH): the patient has experienced an inadequate

treatment response, intolerance, or has a contraindication to both of the following: 1)

alpha blocker, 2) 5-alpha reductase inhibitor (5-ARI).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 26 weeks

Other Criteria -

Prior Authorization GroupTADALAFIL (PAH)Drug NamesALYQ, TADALAFIL

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group

1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1)
Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2)
Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
AND 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood

units.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TAFINLAR
Drug Names TAFINLAR

Drug NamesTAFINLARPA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Langerhans cell histiocytosis, Erdheim-Chester disease.

Exclusion Criteria -

Required Medical Information For melanoma: 1) The tumor is positive for a BRAF V600 activating mutation (e.g.,

V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with trametinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested drug will be used as a single agent or in combination with trametinib. For papillary, follicular, and oncocytic thyroid carcinoma: 1) The tumor is BRAF V600E-positive, AND 2) The disease is not amenable to radioactive iodine (RAI) therapy, AND 3) the requested drug will be used in combination with trametinib. For Langerhans Cell Histiocytosis and Erdheim-Chester Disease: The disease is positive for a BRAF V600E mutation. For solid tumors: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested drug will be used in

combination with trametinib.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TAGRISSO

Drug Names TAGRISSO

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent non-small cell lung cancer (NSCLC), brain metastases from sensitizing EGFR mutation-positive NSCLC, leptomeningeal metastases from EGFR mutation-positive NSCLC

Exclusion Criteria

Required Medical Information For non-small cell lung cancer (NSCLC), the requested drug is used in any of the

following settings: 1) The patient meets both of the following: a) patient has unresectable, metastatic, advanced, or recurrent NSCLC (including brain and/or leptomeningeal metastases from NSCLC) and b) patient has a sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease, OR 2) The patient meets both

of the following: a) request is for adjuvant treatment of NSCLC following tumor

resection and b) patient has EGFR mutation-positive disease.

Age Restrictions

Prescriber Restrictions - Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TALZENNA
Drug Names TALZENNA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent germline breast cancer susceptibility gene (BRCA)-mutated breast cancer

Exclusion Criteria -

Required Medical Information

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TARGRETIN TOPICAL

Drug Names BEXAROTENE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Mycosis fungoides (MF)/Sezary syndrome (SS), chronic or smoldering adult T-cell

leukemia/lymphoma (ATLL), primary cutaneous marginal zone lymphoma, primary

cutaneous follicle center lymphoma

Exclusion Criteria -

Required Medical Information

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

NILOTINIB HYDROCHLORIDE, TASIGNA

TASIGNA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumor (GIST), myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase, pigmented

villonodular synovitis/tenosynovial giant cell tumor, cutaneous melanoma.

Exclusion Criteria

Required Medical Information

For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor for CML, patient is negative for T315I, Y253H, E255K/V, and F359V/C/I mutations. For acute lymphoblastic leukemia (ALL), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If the patient has experienced resistance to an alternative tyrosine kinase inhibitor for ALL, patient is negative for T315I, Y253H, E255K/V, F359V/C/I and G250E mutations. For gastrointestinal stromal tumor (GIST): 1) Disease is residual, unresectable, recurrent/progressive, or metastatic/tumor rupture, AND 2) Disease has progressed on at least 2 Food and Drug Administration (FDA)-approved therapies (e.g. imatinib, sunitinib, regorafenib, ripretinib). For cutaneous melanoma: 1) Disease is metastatic or unresectable, AND 2) Disease is positive for c-KIT activating mutations, AND 3) Requested drug will be used as subsequent therapy,

AND 4) Patient has had disease progression, intolerance, or risk of progression with

BRAF-targeted therapy.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTAVNEOSDrug NamesTAVNEOS

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For continuation of treatment for severe anti-neutrophil cytoplasmic autoantibody

(ANCA)-associated vasculitis: the patient has experienced benefit from therapy.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TAZAROTENE

Drug NamesTAZAROTENE, TAZORACPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For plaque psoriasis, the patient meets the following criteria: 1) the patient has less

than or equal to 20 percent of affected body surface area (BSA), AND 2) the patient experienced an inadequate treatment response or intolerance to at least one topical

corticosteroid OR has a contraindication that would prohibit a trial of topical

corticosteroids.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTAZVERIKDrug NamesTAZVERIK

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria -

Required Medical Information -

Age Restrictions Epithelioid sarcoma: 16 years of age or older, Follicular lymphoma: 18 years of age or

older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Drug Names

TECENTRIQ TECENTRIQ

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Single agent maintenance for extensive small cell lung cancer following combination

treatment with etoposide and carboplatin, subsequent therapy for peritoneal

mesothelioma, pericardial mesothelioma, and tunica vaginalis testis mesothelioma, urothelial carcinoma, stage IIIB non-small cell lung cancer (NSCLC), persistent,

recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC).

Exclusion Criteria

Required Medical Information

For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced, or metastatic disease OR 2) the patient has stage II to IIIB disease AND the requested

drug will be used as adjuvant treatment following resection and adjuvant

chemotherapy. For hepatocellular carcinoma, the requested drug will be used as initial

treatment in combination with bevacizumab.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

PA Indication Indicator

Off-label Uses

TECENTRIQ HYBREZA

TECENTRIQ HYBREZA

All FDA-approved Indications, Some Medically-accepted Indications

Persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC), stage IIIB non-small cell lung cancer (NSCLC), subsequent therapy for

peritoneal mesothelioma, pericardial mesothelioma, and tunica vaginalis testis

mesothelioma.

Exclusion Criteria

Required Medical Information

For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced or

metastatic disease OR 2) the patient has stage II to IIIB disease AND the requested

drug will be used as adjuvant treatment following resection and adjuvant

chemotherapy. For hepatocellular carcinoma, the requested drug will be used as initial

treatment in combination with bevacizumab.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Plan Year

Other Criteria

_

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization GroupTEMAZEPAMDrug NamesTEMAZEPAM

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For short-term treatment of insomnia: 1) The prescriber must acknowledge that the

benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) AND 2) The patient has experienced an inadequate treatment

response, intolerance, or has a contraindication to doxepin (3 mg or 6 mg).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria This Prior Authorization only applies to patients 65 years of age or older.

Prior Authorization GroupTEPMETKODrug NamesTEPMETKO

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Recurrent non-small cell lung cancer (NSCLC), NSCLC with high level mesenchymalepithelial transition (MET) amplification, central nervous system (CNS) cancer including

brain metastases and leptomeningeal metastases from MET exon-14 mutated NSCLC

Exclusion Criteria -

Required Medical Information For recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC): Tumor is

positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutation.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTERBINAFINE TABSDrug NamesTERBINAFINE HCL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the treatment of onychomycosis due to dermatophytes (tinea unguium), patient

meets ALL of the following: 1) the patient will use the requested drug orally., AND 2)

the requested drug is being prescribed for non-continuous use.

Age Restrictions -

Prescriber Restrictions

Coverage Duration 12 weeks

Other Criteria Prior authorization applies to greater than cumulative 90 days of therapy per year.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

PA Indication Indicator

Off-label Uses
Exclusion Criteria

Required Medical Information

TERIPARATIDE

BONSITY, TERIPARATIDE All FDA-approved Indications

For postmenopausal osteoporosis: patient has ONE of the following: 1) history of

fragility fracture, OR 2) pre-treatment T-score of less than or equal to -2.5 or pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment Fracture Risk Assessment Tool (FRAX) fracture probability AND patient has ANY of the following: a) indicators for higher fracture risk (e.g., advanced age, frailty, glucocorticoid

therapy, very low T-scores, or increased fall risk), OR b) patient has failed prior treatment with or is intolerant to a previous injectable osteoporosis therapy OR c) patient has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate. For primary or hypogonadal osteoporosis in men: patient has ONE of the following: 1) history of

to -2.5, or pre-treatment T-score greater than -2.5 and less than -1 with a high pretreatment FRAX fracture probability AND patient has ANY of the following: a) patient has failed prior treatment with or is intolerant to a previous injectable osteoporosis therapy, OR b) patient has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate. For

osteoporotic vertebral or hip fracture, OR 2) pre-treatment T-score of less than or equal

glucocorticoid-induced osteoporosis: patient has had an oral bisphosphonate trial of at least 1-year duration unless patient has a contraindication or intolerance to an oral bisphosphonate, AND patient meets ANY of the following: 1) patient has a history of fragility fracture, OR 2) pre-treatment T-score of less than or equal to -2.5, OR 3) pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment FRAX

fracture probability.

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

Initial: 24 months, Continuation: Plan Year

Continuation of therapy: If the patient has received greater than or equal to 24 months of therapy with any parathyroid hormone analog: 1) The patient remains at or has returned to having a high risk for fracture, AND 2) The benefit of therapy with this prescribed medication outweighs the potential risks for this patient. Patient has high FRAX fracture probability if the 10-year probability is either greater than or equal to 20 percent for any major osteoporotic fracture or greater than or equal to 3 percent for hip fracture. If glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) per day, the estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Drug Names

TESTOSTERONE CYPIONATE INJ

DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE

PA Indication Indicator Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Exclusion Criteria

Gender Dysphoria

Required Medical Information

For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

Prior Authorization Group

Drug Names

PA Indication Indicator

Off-label Uses

Exclusion Criteria

Required Medical Information

TESTOSTERONE ENANTHATE INJ TESTOSTERONE ENANTHATE

decision to engage in hormone therapy.

All FDA-approved Indications, Some Medically-accepted Indications

Gender Dysphoria

For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The

patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on

the reference laboratory range or current practice guidelines before starting

testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed

decision to engage in hormone therapy.

Age Restrictions

Prescriber Restrictions

Coverage Duration

Other Criteria

Plan Year

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group TETRABENAZINE
Drug Names TETRABENAZINE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Tic disorders, tardive dyskinesia, hemiballismus, chorea not associated with

Huntington's disease.

Exclusion Criteria -

Required Medical Information For treatment of tardive dyskinesia and treatment of chorea associated with

Huntington's disease: The patient has experienced an inadequate treatment response

or intolerable adverse event to deutetrabenazine.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group THALOMID

Drug Names THALOMID

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myelofibrosis-associated anemia, acquired immunodeficiency syndrome (AIDS)-related

aphthous stomatitis, Kaposi sarcoma, multicentric Castleman's disease, Rosai-Dorfman

disease, Langerhans cell histiocytosis

Exclusion Criteria -

Required Medical Information -

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TIBSOVO Drug Names TIBSOVO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Conventional (grades 1-3) or dedifferentiated chondrosarcoma, central nervous system

(CNS) cancers (astrocytoma, oligodendroglioma)

Exclusion Criteria

Required Medical Information Patient has disease with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. For

> acute myeloid leukemia (AML): 1) patient has newly-diagnosed AML and meets one of the following: a) 75 years of age or older, b) patient has comorbidities that preclude use of intensive induction chemotherapy, OR 2) the requested drug will be used as postinduction therapy following response to induction therapy with the requested drug, OR 3) patient has relapsed or refractory AML. For locally advanced, unresectable, resected gross residual, or metastatic cholangiocarcinoma: the requested drug will be used as subsequent treatment for progression on or after systemic treatment. For CNS cancers:

1) disease is recurrent or progressive, AND 2) patient has oligodendroglioma or

astrocytoma.

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year Other Criteria

Prior Authorization Group TOBI INHALER TOBI PODHALER

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Non-cystic fibrosis bronchiectasis

Exclusion Criteria

Drug Names

Required Medical Information For cystic fibrosis and non-cystic fibrosis bronchiectasis: 1) Pseudomonas aeruginosa

is present in the patient's airway cultures, OR 2) The patient has a history of

Pseudomonas aeruginosa infection or colonization in the airways.

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization GroupTOBRAMYCINDrug NamesTOBRAMYCIN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Non-cystic fibrosis bronchiectasis

Exclusion Criteria -

Required Medical Information For cystic fibrosis and non-cystic fibrosis bronchiectasis: 1) Pseudomonas aeruginosa

is present in the patient's airway cultures, OR 2) The patient has a history of

Pseudomonas aeruginosa infection or colonization in the airways.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group TOPICAL LIDOCAINE

Drug Names GLYDO, LIDOCAINE, LIDOCAINE HYDROCHLORIDE

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information 1) The requested drug is being used for topical anesthesia, AND 2) If the requested

drug will be used as part of a compounded product, then all the active ingredients in the compounded product are Food and Drug Administration (FDA) approved for topical

use.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 3 months

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group TOPICAL TACROLIMUS

Drug Names TACROLIMUS

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Psoriasis on the face, genitals, or skin folds.

Exclusion Criteria -

Required Medical Information For moderate to severe atopic dermatitis (eczema): the patient meets either of the

following criteria: 1) the disease affects sensitive skin areas (e.g., face, genitals, or skin

folds), OR 2) the patient has experienced an inadequate treatment response,

intolerance, or contraindication to at least one first line therapy agent (e.g., medium or higher potency topical corticosteroid). For all indications: the requested drug is being

prescribed for short-term or non-continuous chronic use.

Age Restrictions Tacrolimus 0.03% 2 years of age or older, Tacrolimus 0.1% 16 years of age or older.

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TOPICAL TESTOSTERONES

Drug Names TESTOSTERONE, TESTOSTERONE PUMP

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Gender Dysphoria

Exclusion Criteria -

Required Medical Information For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The

patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on

the reference laboratory range or current practice guidelines before starting

testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed

decision to engage in hormone therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization Group TOPICAL TRETINOIN

Drug Names TRETINOIN

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria - Required Medical Information -

Age Restrictions - Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TOREMIFENE

Drug NamesTOREMIFENE CITRATEPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -

Exclusion Criteria Congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or

uncorrected hypomagnesemia.

Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group Drug Names

TRAZIMERA All FDA-approved Indications, Some Medically-accepted Indications

PA Indication Indicator Off-label Uses

Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma. HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer. intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-postiive endometrial cancer.

Exclusion Criteria Required Medical Information

TRAZIMERA

For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2 positive and 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the requested drug is being used in combination with

carboplatin and paclitaxel and 2) continued as a single agent for maintenance therapy.

Age Restrictions **Prescriber Restrictions Coverage Duration** Other Criteria

Plan Year

Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.

10/4/18 H8197 NSR 19 MMP 272 TXPAgrid

Prior Authorization Group TREMFYA

Drug Names TREMFYA, TREMFYA INDUCTION PACK FO

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts): 1) at least 3% of body surface

area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, scalp, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous

areas] are affected).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTREPROSTINIL INJDrug NamesTREPROSTINIL

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (World Health Organization [WHO] Group 1): PAH

was confirmed by right heart catheterization. For new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) pretreatment

pulmonary vascular resistance is greater than or equal to 3 Wood units.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group TRIENTINE

Drug NamesTRIENTINE HYDROCHLORIDEPA Indication IndicatorAll FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTRIKAFTADrug NamesTRIKAFTA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For cystic fibrosis: The requested medication will not be used in combination with other

medications containing ivacaftor.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTRINTELLIXDrug NamesTRINTELLIX

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For major depressive disorder (MDD): The patient has experienced an inadequate

treatment response, intolerance, or the patient has a contraindication to ONE of the following generic products: serotonin and norepinephrine reuptake inhibitors (SNRIs),

selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Updated: 10/01/2025 146

Prior Authorization Group TRULICITY
Drug Names TRULICITY

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions For glycemic control in type 2 diabetes mellitus:10 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupTRUQAPDrug NamesTRUQAP

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group Drug Names PA Indication Indicator Off-label Uses TRUXIMA TRUXIMA

All FDA-approved Indications, Some Medically-accepted Indications Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell lymphoma, marginal zone lymphomas (nodal, splenic, extranodal marginal zone lymphoma), Burkitt lymphoma, high-grade B-cell lymphoma, histological transformation from indolent lymphomas to diffuse large B-cell lymphoma, histological transformation chronic lymphocytic leukemia (CLL)/SLL to diffuse large B-cell lymphoma, primary cutaneous B-cell lymphoma, Castleman disease, human immunodeficiency virus (HIV)related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease (GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary central nervous system (CNS) lymphoma, leptomeningeal metastases from lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)related PTLD, multiple sclerosis, immune checkpoint inhibitor-related toxicities, Rosai-Dorfman disease, pemphigus vulgaris, pediatric aggressive mature B-cell lymphomas (including Burkitt-like lymphoma, primary mediastinal large B-cell lymphoma), and pediatric mature B-cell acute leukemia

Exclusion Criteria
Required Medical Information

_

For moderately to severely active rheumatoid arthritis (new starts only): 1) patient meets ANY of the following: a) requested drug will be used in combination with methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2) patient meets ANY of the following: a) inadequate response, intolerance, or contraindication to MTX OR b) inadequate response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has a diagnosis of relapsing remitting multiple sclerosis, AND 2) patient has had an inadequate response to two or more disease-modifying drugs indicated for multiple sclerosis despite adequate duration of treatment.

Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria

-

Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year

-

Updated: 10/01/2025 148

Prior Authorization GroupTUKYSADrug NamesTUKYSA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer

Exclusion Criteria -

Required Medical Information For colorectal cancer (including appendiceal adenocarcinoma): 1) the patient has

advanced, unresectable, or metastatic disease, AND 2) the patient has human epidermal growth factor receptor 2 (HER2)-positive disease, AND 3) the patient has RAS wild-type disease, AND 4) the requested drug will be used in combination with trastuzumab. AND 5) the patient has not previously been treated with a HER2 inhibitor.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TURALIO
Drug Names TURALIO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease

Exclusion Criteria -

Required Medical Information For Langerhans cell histiocytosis: 1) disease has colony stimulating factor 1 receptor

(CSF1R) mutation. For Erdheim-Chester disease and Rosai-Dorfman disease: 1) disease has CSF1R mutation AND patient has any of the following: a) symptomatic

disease OR b) relapsed/refractory disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group TYENNE
Drug Names TYENNE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Castleman's disease, systemic sclerosis-associated interstitial lung disease

Exclusion Criteria -

Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): 1) Patient has

experienced an inadequate treatment response, intolerance or contraindication to methotrexate (MTX) OR 2) Patient has experienced an inadequate response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a

targeted synthetic DMARD.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group UBRELVY UBRELVY Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses **Exclusion Criteria**

For acute treatment of migraine: The patient has experienced an inadequate treatment Required Medical Information

response, intolerance, or the patient has a contraindication to at least one triptan 5-HT1

receptor agonist.

Age Restrictions

Prescriber Restrictions

Plan Year Coverage Duration

Other Criteria

Prior Authorization Group UCERIS

BUDESONIDE ER Drug Names

PA Indication Indicator All FDA-approved Indications

Off-label Uses

Exclusion Criteria

Required Medical Information For the induction of remission of active, mild to moderate ulcerative colitis: patient has

experienced an inadequate treatment response, intolerance, or has a contraindication

to at least one 5-aminosalicylic acid (5-ASA) therapy.

Age Restrictions

Prescriber Restrictions

2 months Coverage Duration

Other Criteria

Prior Authorization Group VALCHLOR VALCHLOR Drug Names

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Chronic or smoldering adult T-cell leukemia/lymphoma (ATLL), Stage 2 or higher

mycosis fungoides (MF)/Sezary syndrome (SS), primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, CD30-positive lymphomatoid papulosis (LyP), unifocal Langerhans cell histiocytosis (LCH) with isolated skin disease

Exclusion Criteria

Required Medical Information

Age Restrictions

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria

Prior Authorization Group VANFLYTA
Drug Names VANFLYTA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Relapsed or refractory acute myeloid leukemia

Exclusion Criteria -

Required Medical Information For acute myeloid leukemia (AML): AML is FMS-like tyrosine kinase 3 (FLT3) internal

tandem duplication (ITD)-positive.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VELCADE

Drug Names BORTEZOMIB

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Systemic light chain amyloidosis, Waldenstrom's

macroglobulinemia/lymphoplasmacytic lymphoma, multicentric Castleman's disease, adult T-cell leukemia/lymphoma, acute lymphoblastic leukemia, Kaposi's sarcoma, pediatric Classic Hodgkin lymphoma, POEMS (polyneuropathy, organomegaly,

endocrinopathy, monoclonal protein, skin changes) syndrome

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group VELSIPITY
Drug Names VELSIPITY

PA Indication Indicator All FDA-approved Indications

Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group

Drug Names

VENCLEXTA, VENCLEXTA STARTING PACK

VENCLEXTA

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Mantle cell lymphoma, blastic plasmacytoid dendritic cell neoplasm (BPDCN), multiple

myeloma, relapsed or refractory acute myeloid leukemia (AML), Waldenstrom

macroglobulinemia/lymphoplasmacytic lymphoma, relapsed or refractory systemic light

chain amyloidosis with translocation t(11:14), accelerated or blast phase

myeloproliferative neoplasms, B-cell acute lymphoblastic leukemia/T-cell acute

lymphoblastic leukemia (B-ALL/T-ALL), hairy cell leukemia

Exclusion Criteria

Required Medical Information

For acute myeloid leukemia (AML): 1) patient has newly-diagnosed AML and meets one of the following: a) 75 years of age or older, b) patient has comorbidities that

preclude use of intensive induction chemotherapy, OR 2) patient has poor/adverse risk disease and is a candidate for intensive induction therapy, OR 3) patient has relapsed or refractory AML. For blastic plasmacytoid dendritic cell neoplasm (BPDCN): 1) patient has systemic disease being treated with palliative intent, OR 2) patient has relapsed or

refractory disease. For multiple myeloma: 1) the disease is relapsed or progressive, AND 2) the requested drug will be used in combination with dexamethasone, AND 3)

patient has t(11:14) translocation. For Waldenstrom

macroglobulinemia/lymphoplasmacytic lymphoma: 1) patient has previously treated disease that did not respond to primary therapy, OR 2) patient has progressive or

relapsed disease.

Age Restrictions

Prescriber Restrictions

Plan Year

Coverage Duration

Other Criteria -

Prior Authorization Group VEOZAH
Drug Names VEOZAH

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VERQUVO
Drug Names VERQUVO

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For symptomatic chronic heart failure: the patient has a left ventricular ejection fraction

(LVEF) less than 45 percent. For initial therapy, the patient meets ANY of the following: 1) hospitalization for heart failure within the past 6 months OR 2) use of outpatient

intravenous diuretics for heart failure within the past 3 months.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupVERSACLOZDrug NamesVERSACLOZ

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For the treatment of a severely ill patient with schizophrenia who failed to respond

adequately to standard antipsychotic treatment (i.e., treatment-resistant schizophrenia):

1) the patient has experienced an inadequate treatment response, intolerance, or has a

contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group VERZENIO

Drug NamesVERZENIOPA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2

(HER2)-negative breast cancer in combination with fulvestrant or an aromatase inhibitor, or as a single agent if progression on prior endocrine therapy and prior chemotherapy in the metastatic setting. Endometrial cancer, in combination with

letrozole for estrogen receptor positive tumor.

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VIGABATRIN

Drug Names VIGABATRIN, VIGADRONE, VIGPODER

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For complex partial seizures (i.e., focal impaired awareness seizures): patient has

experienced an inadequate treatment response to at least two antiepileptic drugs for

complex partial seizures (i.e., focal impaired awareness seizures).

Age Restrictions Infantile Spasms: 1 month to 2 years of age. Complex partial seizures (i.e., focal

impaired awareness seizures): 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VIGAFYDE Drug Names VIGAFYDE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Required Medical Information -

Age Restrictions Infantile Spasms: 1 month to 2 years of age

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VITRAKVI
Drug Names VITRAKVI

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Non-metastatic neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid

tumors, first-line treatment of NTRK gene fusion-positive solid tumors.

Exclusion Criteria

Required Medical Information For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors,

the disease is without a known acquired resistance mutation.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupVIZIMPRODrug NamesVIZIMPRO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent non-small cell lung cancer (NSCLC)

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or

metastatic, and 2) the patient has sensitizing epidermal growth factor receptor (EGFR)

mutation-positive disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VONJO Drug Names VONJO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Accelerated or blast phase myeloproliferative neoplasms

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupVORANIGODrug NamesVORANIGO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupVORICONAZOLEDrug NamesVORICONAZOLE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information The patient will use the requested drug orally or intravenously.

Age Restrictions - Prescriber Restrictions -

Coverage Duration 6 months

Other Criteria -

Prior Authorization GroupVOSEVIDrug NamesVOSEVI

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh

class B or C)

Required Medical Information For hepatitis C: Infection confirmed by presence of HCV RNA in the serum prior to

starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of HIV coinfection, presence or absence of

resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases

Society of America (AASLD-IDSA) treatment guidelines.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance.

Other Criteria -

Prior Authorization Group VOTRIENT

Drug Names PAZOPANIB HYDROCHLORIDE

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Thyroid carcinoma (follicular, papillary, oncocytic, or medullary), uterine sarcoma,

chondrosarcoma, gastrointestinal stromal tumor

Exclusion Criteria -

Required Medical Information For renal cell carcinoma: 1) the disease is advanced, relapsed, or stage IV, OR 2) the

requested drug will be used for von Hippel-Lindau (VHL)-associated renal cell carcinoma. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture AND 2) the patient meets one of the following: a) the disease has progressed after at least two FDA-approved therapies

(e.g., imatinib, sunitinib, regorafenib, ripretinib), b) the disease is succinate

dehydrogenase (SDH)-deficient GIST. For soft tissue sarcoma (STS): the patient does

not have an adipocytic soft tissue sarcoma.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group VOWST Drug Names VOWST

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the prevention of recurrence of Clostridioides difficile infection (CDI): 1) The

diagnosis of CDI has been confirmed by a positive stool test for C. difficile toxin, AND 2) The requested drug will be administered at least 48 hours after the last dose of

antibiotics used for the treatment of recurrent CDI.

Age Restrictions 18 years of age or older

Prescriber Restrictions -

Coverage Duration 1 month

Other Criteria -

Prior Authorization Group WELIREG
Drug Names WELIREG

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupWYOSTDrug NamesWYOST

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For hypercalcemia of malignancy: condition is refractory to intravenous (IV)

bisphosphonate therapy or there is a clinical reason to avoid IV bisphosphonate

therapy.

XALKORI

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group

Drug Names XALKORI

PA Indication Indicator

Off-label Uses

All FDA-approved Indications, Some Medically-accepted Indications

Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level MET

amplification or MET exon 14 skipping mutation, symptomatic or relapsed/refractory anaplastic lymphoma kinase (ALK)-fusion positive Erdheim-Chester Disease, symptomatic or relapsed/refractory (ALK)-fusion positive Rosai-Dorfman Disease,

(ALK)-fusion positive Langerhans Cell Histiocytosis, metastatic or unresectable ROS1

gene fusion positive cutaneous melanoma.

Exclusion Criteria

Required Medical Information

For non-small cell lung cancer (NSCLC), the requested drug is used in any of the following settings: 1) the patient has recurrent, advanced or metastatic anaplastic

lymphoma kinase (ALK)-positive NSCLC AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib), OR 3) the patient has recurrent, advanced or metastatic ROS-1 positive NSCLC, OR 4) the patient has NSCLC with high-level MET amplification or MET exon 14 skipping mutation. For inflammatory myofibroblastic tumor (IMT), the disease is ALK-positive. For anaplastic large cell lymphoma (ALCL): 1) the disease is relapsed or refractory. AND 2) the

disease is ALK-positive.

Age Restrictions

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group XDEMVY
Drug Names XDEMVY

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group XELJANZ

Drug NamesXELJANZ, XELJANZ XRPA Indication IndicatorAll FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information

For moderately to severely active rheumatoid arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For active psoriatic arthritis (new starts only): 1) Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumabaacfl) AND 2) the requested drug is used in combination with a nonbiologic DMARD. For active ankylosing spondylitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active ulcerative colitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumabaacf]). For active polyarticular course juvenile idiopathic arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumabaacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]).

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization GroupXERMELODrug NamesXERMELO

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupXGEVADrug NamesXGEVA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For hypercalcemia of malignancy: condition is refractory to intravenous (IV)

bisphosphonate therapy or there is a clinical reason to avoid IV bisphosphonate

therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization Group XHANCE
Drug Names XHANCE

PA Indication Indicator All FDA-approved Indications

Off-label Uses Exclusion Criteria Required Medical Information -

Age Restrictions 18 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group XIFAXAN
Drug Names XIFAXAN

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Small intestinal bacterial overgrowth syndrome (SIBO)

Exclusion Criteria -

Required Medical Information For irritable bowel syndrome with diarrhea (IBS-D): 1) The patient has not previously

received treatment with the requested drug, OR 2) The patient has previously received treatment with the requested drug, AND a) the patient is experiencing a recurrence of symptoms, AND b) the patient has not already received an initial 14-day course of treatment and two additional 14-day courses of treatment with the requested drug. For small intestinal bacterial overgrowth (SIBO): 1) the patient is experiencing a recurrence after completing a successful course of treatment with the requested drug OR 2) diagnosis has been confirmed by one of the following: a) quantitative culture of upper gut aspirate, b) breath testing (e.g., lactulose hydrogen or glucose hydrogen breath

test).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Reduction in risk of overt HE recurrence: 6 months, IBS-D and SIBO: 14 days

Other Criteria -

Prior Authorization GroupXOLAIRDrug NamesXOLAIR

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information

For moderate to severe persistent asthma, initial therapy (tx): 1) Patient (pt) has a positive skin test (or blood test) to at least one perennial aeroallergen, 2) Pt has baseline immunoglobulin E (IgE) level greater than or equal to 30 international units per milliliter (IU/mL), AND 3) Pt has inadequate asthma control despite current tx with both of the following medications: a) Medium-to-high-dose inhaled corticosteroid, AND b) Additional controller (i.e., long acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless pt has an intolerance or contraindication to such therapies. For moderate to severe persistent asthma, continuation of tx (COT): Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms (sx) and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For chronic spontaneous urticaria (CSU), initial tx: 1) Pt has been evaluated for other causes of urticaria, including bradykinin-related angioedema and interleukin-1 (IL-1)associated urticarial syndromes (e.g., auto-inflammatory disorders, urticarial vasculitis), 2) Pt has experienced a spontaneous onset of wheals, angioedema, or both, for at least 6 weeks, AND 3) Pt remains symptomatic despite H1 antihistamine treatment. For CSU, COT: Pt has experienced a benefit (e.g., improved sx) since initiation of tx. For chronic rhinosinusitis with nasal polyps (CRSwNP): 1) The requested drug is used as add-on maintenance treatment, AND 2) Pt has experienced inadequate treatment response to Xhance (fluticasone). For IgE-mediated food allergy, initial tx: Pt has baseline IgE level greater than or equal to 30 IU/mL. For IgE-mediated food allergy, COT: Pt has experienced a benefit as evidenced by a decrease in hypersensitivity (e.g., moderate to severe skin, respiratory or gastrointestinal sx) to food allergen. CSU: 12 years of age or older. Asthma: 6 years of age or older. CRSwNP: 18 years of age or older. IgE-mediated food allergy: 1 year of age or older

Age Restrictions

Prescriber Restrictions

Coverage Duration CSU initial: 6 months, All others: Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid

Updated: 10/01/2025 162

10/4/18

Prior Authorization Group XOSPATA
Drug Names XOSPATA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FLT3

rearrangement

Exclusion Criteria -

Required Medical Information For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FMS-like

tyrosine kinase 3 (FLT3) rearrangement: the disease is in chronic or blast phase.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group XPOVIO

Drug Names

XPOVIO, XPOVIO 60 MG TWICE WEEKLY, XPOVIO 80 MG TWICE WEEKLY

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma,

Human Immunodeficiency Virus (HIV)-related B-cell lymphoma, high-grade B-cell

lymphoma, post-transplant lymphoproliferative disorders

Exclusion Criteria

Required Medical Information For multiple myeloma: Patient must have been treated with at least one prior therapy.

For B-cell lymphomas: Patient must have been treated with at least two lines of

systemic therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group XTANDI Drug Names XTANDI

PA Indication Indicator All FDA-approved Indications

Off-label Uses -

Exclusion Criteria -

Required Medical Information For the treatment of castration-resistant prostate cancer or metastatic castration-

sensitive prostate cancer: The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group XYREM

Drug Names SODIUM OXYBATE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For the treatment of excessive daytime sleepiness in a patient with narcolepsy, initial

request: 1) The diagnosis has been confirmed by sleep lab evaluation, AND 2) The patient meets one of the following criteria: a) if the patient is 17 years of age or younger, the patient has experienced an inadequate treatment response or intolerance to at least one central nervous system (CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, methylphenidate), OR has a contraindication that would prohibit a trial of central nervous system (CNS) stimulant drugs (e.g., amphetamine, dextroamphetamine, methylphenidate), b) If the patient is 18 years of age or older, the patient has experienced an inadequate treatment response or intolerance to at least one central nervous system (CNS) wakefulness promoting drug (e.g., armodafinil, modafinil), OR has a contraindication that would prohibit a trial of central nervous system (CNS) wakefulness promoting drugs (e.g., armodafinil, modafinil). For the treatment of cataplexy in a patient with narcolepsy, initial request: The diagnosis has been confirmed by sleep lab evaluation. If the request is for a continuation of therapy,

then the patient experienced a decrease in daytime sleepiness with narcolepsy or a

decrease in cataplexy episodes with narcolepsy.

Age Restrictions 7 years of age or older

Prescriber Restrictions Prescribed by or in consultation with a sleep disorder specialist or neurologist

Coverage Duration Plan Year
Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Prior Authorization Group YESINTEK
Drug Names YESINTEK

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body

surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group YONSA
Drug Names YONSA

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Exclusion Criteria -

Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone

(GnRH) analog or after bilateral orchiectomy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

Updated: 10/01/2025 165

Prior Authorization Group YUTREPIA
Drug Names YUTREPIA

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)

or pulmonary hypertension (PH) associated with interstitial lung disease (WHO Group 3): the diagnosis was confirmed by right heart catheterization. For new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)

pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood

units.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupZARXIODrug NamesZARXIO

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Neutropenia in myelodysplastic syndromes (MDS), agranulocytosis, neutropenia in

aplastic anemia, human immunodeficiency virus (HIV)-related neutropenia

Exclusion Criteria -

Required Medical Information If receiving chemotherapy, the requested drug will be administered at least 24 hours

after chemotherapy. For prophylaxis or treatment of myelosuppressive chemotherapyinduced febrile neutropenia (FN) patient must meet both of the following: 1) Patient has

a solid tumor or non-myeloid cancer, AND 2) Patient has received, is currently receiving, or will be receiving treatment with myelosuppressive anti-cancer therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 6 months

Other Criteria -

Prior Authorization GroupZEJULADrug NamesZEJULA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Uterine leiomyosarcoma

Exclusion Criteria -

Required Medical Information For uterine leiomyosarcoma: 1) the requested drug is used as second-line therapy AND

2) the patient has BRCA-altered disease.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupZELBORAFDrug NamesZELBORAF

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses

Non-small cell lung cancer, hairy cell leukemia, central nervous system cancer (i.e., glioma, glioblastoma, pediatric diffuse high-grade glioma), adjuvant systemic therapy

for cutaneous melanoma, Langerhans cell histiocytosis.

Exclusion Criteria

Required Medical Information For central nervous system (CNS) cancer (i.e., glioma, astrocytoma, glioblastoma,

pediatric diffuse high-grade glioma): 1) The tumor is positive for BRAF V600E mutation, AND 2) The requested drug will be used in combination with cobimetinib OR the requested drug is being used for the treatment of pediatric diffuse high-grade glioma.

For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) the requested drug will be used as a single agent, or in combination with cobimetinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, or b) adjuvant systemic therapy. For Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Tumor is positive for BRAF V600 mutation. For non-small cell lung cancer: 1) The tumor is positive for the BRAF V600E mutation, AND 2) The patient has recurrent,

advanced, or metastatic disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

H8197_NSR_19_MMP_272_TXPAgrid 10/4/18

Prior Authorization Group ZIRABEV
Drug Names ZIRABEV

PA Indication Indicator

All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Ampullary adenocarcinoma, appendiceal adenocarcinoma, breast cancer, central

nervous system (CNS) cancers (including pediatric diffuse high-grade gliomas), pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, tunica vaginalis testis mesothelioma, soft tissue sarcomas, uterine neoplasms, endometrial carcinoma, vulvar cancers, small bowel adenocarcinoma, and ophthalmic-related disorders: diabetic macular edema, neovascular (wet) age-related macular degeneration including

polypoidal choroidopathy and retinal angiomatous proliferation subtypes, macular edema following retinal vein occlusion, proliferative diabetic retinopathy, choroidal

neovascularization, neovascular glaucoma and retinopathy of prematurity

Exclusion Criteria -

Required Medical Information -

Age Restrictions -

Prescriber Restrictions

Coverage Duration Plan Year

Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as

the medication is prescribed and dispensed or administered for the individual.

Prior Authorization GroupZOLINZADrug NamesZOLINZA

PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Mycosis fungoides (MF)/Sezary syndrome (SS)

Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupZONISADEDrug NamesZONISADE

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -

Required Medical Information For adjunctive treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The

patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom, Xcopri, Spritam OR 2) The patient has difficulty swallowing solid oral

dosage forms (e.g., tablets, capsules).

Age Restrictions 16 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupZTALMYDrug NamesZTALMY

PA Indication Indicator All FDA-approved Indications

Off-label Uses -Exclusion Criteria -Required Medical Information -

Age Restrictions 2 years of age or older

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization GroupZURZUVAEDrug NamesZURZUVAE

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information For the treatment of postpartum depression (PPD): diagnosis was confirmed using

standardized rating scales that reliably measure depressive symptoms (e.g., Hamilton Depression Rating Scale [HDRS], Edinburgh Postnatal Depression Scale [EPDS], Patient Health Questionnaire 9 [PHQ9], Montgomery-Asberg Depression Rating Scale

[MADRS], Beck's Depression Inventory [BDI], etc.).

Age Restrictions -

Prescriber Restrictions -

Coverage Duration 1 month

Other Criteria -

Prior Authorization GroupZYDELIGDrug NamesZYDELIG

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Small lymphocytic lymphoma (SLL)

Exclusion Criteria -

Required Medical Information For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): the

requested drug is used as second-line or subsequent therapy.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Prior Authorization Group ZYKADIA
Drug Names ZYKADIA

PA Indication IndicatorAll FDA-approved Indications, Some Medically-accepted Indications

Off-label Uses Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer

(NSCLC), recurrent, advanced, or metastatic ROS1-positive NSCLC, Erdheim-Chester Disease (ECD) with ALK-fusion, inflammatory myofibroblastic tumor (IMT), brain metastases from NSCLC, relapsed or refractory ALK-positive anaplastic large cell

lymphoma (ALCL)

Exclusion Criteria -

Required Medical Information For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced, or

metastatic anaplastic lymphoma kinase (ALK)-positive AND 2) the patient has

experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib) OR 3) ROS1-positive disease. For inflammatory myofibroblastic tumor: the disease is ALK-positive. For brain metastases from NSCLC: the patient has ALK-positive NSCLC. For anaplastic large cell lymphoma (ALCL): the patient has relapsed or refractory ALK-

positive disease.

Age Restrictions -

Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Updated: 10/01/2025 170

Prior Authorization GroupZYPREXA RELPREVVDrug NamesZYPREXA RELPREVV

PA Indication Indicator All FDA-approved Indications

Off-label Uses - Exclusion Criteria -

Required Medical Information Tolerability with oral olanzapine has been established.

Age Restrictions Prescriber Restrictions -

Coverage Duration Plan Year

Other Criteria -

Molina Dual Options STAR+PLUS MMP is a health plan that contracts with both Medicare and Texas Medicaid to provide benefits of both programs to enrollees.

You can get this document for free in other formats, such as large print, braille, or audio. Call (866) 856-8699, TTY: 711, Monday – Friday, 8 a.m. to 8 p.m., local time. The call is free.

https://www.molinahealthcare.com/members/common/en-US/multi-language-taglines.aspx

Molina Healthcare complies with applicable Federal civil rights laws and does not discriminate on the basis of age, color, disability, national origin (including limited English proficiency), race, or sex (consistent with the scope of sex discrimination described at § 92.101(a)).

To help you effectively communicate with us, Molina Healthcare provides services free of charge and in a timely manner:

- Molina Healthcare provides reasonable modifications and appropriate aids and services to people with disabilities. This includes: (1) Qualified interpreters. (2) Information in other formats, such as large print, audio, accessible electronic formats, Braille.
- Molina Healthcare provides language services to people who speak another language or have limited English skills. This includes: (1) Qualified oral interpreters. (2) Information translated in your language.

If you need these services, contact Molina Member Services at 1-800-665-3086 or TTY/TDD: 711, Monday to Friday, 8 a.m. to 8 p.m., local time.

If you believe we have discriminated on the basis of age, color, disability, national origin, race, or sex, you can file a grievance. You can file a grievance by phone, mail, email, or online. If you need help writing your grievance, we will help you. You may obtain our grievance procedure by visiting our website at https://www.molinahealthcare.com/members/common/en-US/Notice-of-Nondiscrimination.aspx

Call our Civil Rights Coordinator at 1-866-606-3889, TTY/TDD: 711 or submit your grievance to:

Civil Rights Unit 200 Oceangate Long Beach, CA 90802

Email: civil.rights@molinahealthcare.com Website: https://molinahealthcare.Alertline.com

H8197 NSR 19 MMP 272 TXPAgrid 10/4/18

You can also file a civil rights complaint (grievance) with the U.S. Department of Health and Human Services, Office for Civil Rights, online through the Office for Civil Rights Complaint Portal at: https://ocrportal.hhs.gov/ocr/portal/lobby.jsf or by mail or phone at:

U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 Phone: 1-800-368-1019

TTY/TDD: 800-537-7697

Complaint forms are available here: https://www.hhs.gov/sites/default/files/ocr-cr-complaint-form-package.pdf

Updated: 10/01/2025 172